

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY INTEREST

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
Amyris, Inc.		10/02/2013	CORPORATION: DELAWARE

RECEIVING PARTY DATA

Name:	Total Energies Nouvelles Activites USA
Street Address:	24 Cours Michelet
City:	Puteaux
State/Country:	FRANCE
Postal Code:	92800
Entity Type:	COMPANY: FRANCE

PROPERTY NUMBERS Total: 15

Property Type	Number	Word Mark
Registration Number:	3418982	
Registration Number:	3591716	
Registration Number:	4031996	AMYRIS
Registration Number:	3418984	AMYRIS
Registration Number:	3516929	AMYRIS
Registration Number:	3604243	GREEN LANE
Registration Number:	3793831	A
Registration Number:	3793830	A
Registration Number:	3846212	NO COMPROMISE
Registration Number:	3664922	NO COMPROMISE
Registration Number:	3726789	
Registration Number:	3894976	BIOFENE
Registration Number:	4209630	NEOSSANCE
Registration Number:	4302622	EVOSHIELD

CH \$390.00 3418982

Serial Number:

85631181

CLEARLY PATCHOULI

CORRESPONDENCE DATA

Fax Number: 6504936811

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.

Phone: 650-461-6125

Email: qlu@wsgr.com

Correspondent Name: WSGR, c/o Qui Lu

Address Line 1: 650 Page Mill Road

Address Line 2: FH2-1 P10

Address Line 4: Palo Alto, CALIFORNIA 94304

ATTORNEY DOCKET NUMBER:

40860.014

DOMESTIC REPRESENTATIVE

Name: Wilson Sonsini Goodrich & Rosati, PC

Address Line 1: 650 Page Mill Road

Address Line 4: Palo Alto, CALIFORNIA 94304

NAME OF SUBMITTER:

Qui Lu

Signature:

/s/ Qui Lu

Date:

10/04/2013

Total Attachments: 98

source=IP Security Agreement#page1.tif
source=IP Security Agreement#page2.tif
source=IP Security Agreement#page3.tif
source=IP Security Agreement#page4.tif
source=IP Security Agreement#page5.tif
source=IP Security Agreement#page6.tif
source=IP Security Agreement#page7.tif
source=IP Security Agreement#page8.tif
source=IP Security Agreement#page9.tif
source=IP Security Agreement#page10.tif
source=IP Security Agreement#page11.tif
source=IP Security Agreement#page12.tif
source=IP Security Agreement#page13.tif
source=IP Security Agreement#page14.tif
source=IP Security Agreement#page15.tif
source=IP Security Agreement#page16.tif
source=IP Security Agreement#page17.tif
source=IP Security Agreement#page18.tif
source=IP Security Agreement#page19.tif
source=IP Security Agreement#page20.tif
source=IP Security Agreement#page21.tif
source=IP Security Agreement#page22.tif
source=IP Security Agreement#page23.tif

TRADEMARK
REEL: 005125 FRAME: 0112

source=IP Security Agreement#page24.tif
source=IP Security Agreement#page25.tif
source=IP Security Agreement#page26.tif
source=IP Security Agreement#page27.tif
source=IP Security Agreement#page28.tif
source=IP Security Agreement#page29.tif
source=IP Security Agreement#page30.tif
source=IP Security Agreement#page31.tif
source=IP Security Agreement#page32.tif
source=IP Security Agreement#page33.tif
source=IP Security Agreement#page34.tif
source=IP Security Agreement#page35.tif
source=IP Security Agreement#page36.tif
source=IP Security Agreement#page37.tif
source=IP Security Agreement#page38.tif
source=IP Security Agreement#page39.tif
source=IP Security Agreement#page40.tif
source=IP Security Agreement#page41.tif
source=IP Security Agreement#page42.tif
source=IP Security Agreement#page43.tif
source=IP Security Agreement#page44.tif
source=IP Security Agreement#page45.tif
source=IP Security Agreement#page46.tif
source=IP Security Agreement#page47.tif
source=IP Security Agreement#page48.tif
source=IP Security Agreement#page49.tif
source=IP Security Agreement#page50.tif
source=IP Security Agreement#page51.tif
source=IP Security Agreement#page52.tif
source=IP Security Agreement#page53.tif
source=IP Security Agreement#page54.tif
source=IP Security Agreement#page55.tif
source=IP Security Agreement#page56.tif
source=IP Security Agreement#page57.tif
source=IP Security Agreement#page58.tif
source=IP Security Agreement#page59.tif
source=IP Security Agreement#page60.tif
source=IP Security Agreement#page61.tif
source=IP Security Agreement#page62.tif
source=IP Security Agreement#page63.tif
source=IP Security Agreement#page64.tif
source=IP Security Agreement#page65.tif
source=IP Security Agreement#page66.tif
source=IP Security Agreement#page67.tif
source=IP Security Agreement#page68.tif
source=IP Security Agreement#page69.tif
source=IP Security Agreement#page70.tif
source=IP Security Agreement#page71.tif
source=IP Security Agreement#page72.tif
source=IP Security Agreement#page73.tif
source=IP Security Agreement#page74.tif
source=IP Security Agreement#page75.tif
source=IP Security Agreement#page76.tif
source=IP Security Agreement#page77.tif
source=IP Security Agreement#page78.tif

source=IP Security Agreement#page79.tif
source=IP Security Agreement#page80.tif
source=IP Security Agreement#page81.tif
source=IP Security Agreement#page82.tif
source=IP Security Agreement#page83.tif
source=IP Security Agreement#page84.tif
source=IP Security Agreement#page85.tif
source=IP Security Agreement#page86.tif
source=IP Security Agreement#page87.tif
source=IP Security Agreement#page88.tif
source=IP Security Agreement#page89.tif
source=IP Security Agreement#page90.tif
source=IP Security Agreement#page91.tif
source=IP Security Agreement#page92.tif
source=IP Security Agreement#page93.tif
source=IP Security Agreement#page94.tif
source=IP Security Agreement#page95.tif
source=IP Security Agreement#page96.tif
source=IP Security Agreement#page97.tif
source=IP Security Agreement#page98.tif

**AMENDED AND RESTATED
INTELLECTUAL PROPERTY SECURITY AGREEMENT**

This Amended and Restated Intellectual Property Security Agreement (as amended, restated, modified or otherwise supplemented from time to time, this “**Security Agreement**”), dated as of October 2, 2013 (the “**Effective Date**”), is executed by Amyris, Inc., a Delaware corporation (together with its successors and assigns, “**Company**”), in favor of Total Energies Nouvelles Activités USA (f/k/a Total Gas & Power USA, SAS) (“**Total**”), and Maxwell (Mauritius) Pte Ltd (“**Maxwell**” and together with Total, each a “**Secured Party**” and collectively, the “**Secured Parties**”).

RECITALS

A. Company and Total have entered into a Securities Purchase Agreement, dated as of July 30, 2012 (as amended, restated, modified or otherwise supplemented from time to time, the “**2012 Purchase Agreement**”), pursuant to which the Company has issued and will issue on the dates specified therein promissory notes (as amended, restated, modified, supplemented, or replaced from time to time, each a “**2012 Note**” and collectively, the “**2012 Notes**”).

B. Company and Total have entered into a Letter Agreement, dated as of March 24, 2013 (as amended, restated, modified or otherwise supplemented from time to time, the “**2012 Letter Agreement**”), pursuant to which the Company entered into the Intellectual Property Security Agreement, dated as of April 26, 2013, executed by the Company in favor of Total (the “**Original Security Agreement**”) and granted to Total, until the Security Release Date (as such term is defined below), the security interest in the Collateral described below.

C. Company and Secured Parties have entered into a Securities Purchase Agreement, dated as of August 8, 2013 (as amended, restated, modified or otherwise supplemented from time to time, the “**2013 Purchase Agreement**”), pursuant to which the Company will issue on the dates specified therein promissory notes (as amended, restated, modified, supplemented, or replaced from time to time, each a “**2013 Note**” and collectively, the “**2013 Notes**”).

D. Company has issued to Maxwell a Senior Promissory Note, dated October 2, 2013, in the original principal amount of \$35,000,000 (as amended, restated, modified or otherwise supplemented from time to time, the “**Senior Note**”).

E. Company and Secured Parties have entered into a Letter Agreement, dated as of August 8, 2013 (as amended, restated, modified or otherwise supplemented from time to time, the “**2013 Letter Agreement**”), pursuant to which the Company has agreed to enter into this Security Agreement and to grant to the Secured Parties, until the Security Release Date (as such term is defined below), the security interest in the Collateral described below.

F. The Company and Total have agreed to amend and restate in its entirety the Original Security Agreement upon the terms and conditions set forth in this Security Agreement.

AGREEMENT

NOW, THEREFORE, in consideration of the above recitals and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, Company hereby agrees with Secured Parties as follows:

1. Definitions and Interpretation. When used in this Security Agreement, the following terms have the following respective meanings:

“**Collateral**” means the Common Collateral and the Total Collateral.

“**Common Collateral**” has the meaning given to that term in Section 2 hereof.

“**Event of Default**” has the meaning set forth in the Senior Note, the 2012 Notes or the 2013 Notes, as applicable.

“**Intercreditor Agreement**” means the Intercreditor Agreement, dated as of the Effective Date, entered into among Company, Total and Maxwell, as amended, restated, modified or otherwise supplemented from time to time.

“**JVCO**” means the Dutch Flex BV (or similar corporate entity) to be jointly owned by the Company and Total to carry out their proposed joint venture regarding diesel and/or jet products from BioFene as contemplated by the 2012 Letter Agreement.

“**Lien**” means any mortgage, pledge, hypothecation, assignment for security, deposit arrangement, encumbrance, lien (statutory or other), charge or other security interest or preferential arrangement in the nature of a security interest of any kind or nature whatsoever (including any conditional sale or other title retention agreement, any easement, right of way or other encumbrance on title to real property, and any financing lease having substantially the same economic effect as any of the foregoing).

“**Loan Documents**” means the 2012 Purchase Agreement, the 2013 Purchase Agreement, the 2012 Notes, the 2013 Notes, the Senior Note and this Security Agreement.

“**Maxwell Obligations**” means all Obligations at any time owed by Company to Maxwell.

“**Notes**” means the Senior Note, the 2012 Notes and the 2013 Notes.

“**Obligations**” means all loans, advances, debts, liabilities and obligations, howsoever arising, owed by Company to Secured Parties of every kind and description (whether or not evidenced by any note or instrument and whether or not for the payment of money), now existing or hereafter arising under or pursuant to the terms of the Notes, the 2012 Purchase Agreement, the 2013 Purchase Agreement and this Security Agreement, including, all interest, fees, charges, expenses,

attorneys' fees and costs and accountants' fees and costs chargeable to and payable by Company hereunder and thereunder, in each case, whether direct or indirect, absolute or contingent, due or to become due, and whether or not arising after the commencement of a proceeding under Title 11 of the United States Code (11 U.S.C. Section 101 et seq.), as amended from time to time (including post-petition interest) and whether or not allowed or allowable as a claim in any such proceeding.

“**Novvi and IFF Agreements**” means the IP License Agreement between Company and Novvi LLC, dated March 26, 2013 and the Joint Development and License Agreement between Company and International Flavors and Fragrances dated April 23, 2013.

“**Patents**” means all patent rights and all rights, title and interests in all patent applications and patents to issue on them, all letters patent or equivalent rights and applications, including utility patents, design patents, statutory invention registrations, and any reissue, reexamination, renewal, supplementary protection certificates, extension, division, provisional, substitution, continuation, or continuation-in-part applications thereto throughout the world.

“**Total Collateral**” means, collectively, the property described on Attachment 2 hereto.

“**Total Obligations**” means all Obligations at any time owed by Company to Total.

“**UCC**” means the Uniform Commercial Code as in effect in the State of California from time to time.

All capitalized terms not otherwise defined herein shall have the respective meanings given in the 2012 Purchase Agreement or the 2013 Purchase Agreement, as applicable.

2. Grant of Security Interest. (a) As security for the Maxwell Obligations, Company hereby pledges to Maxwell and grants to Maxwell a security interest of first priority in all right, title and interests of Company in and to the property described in Attachment 1 hereto, whether now existing or hereafter from time to time acquired (collectively, the “**Common Collateral**”).

(b) As security for the Total Obligations, Company hereby pledges to Total and grants to Total a security interest of first priority in all right, title and interests of Company in and to the Common Collateral and the Total Collateral, in each case whether now existing or hereafter from time to time acquired.

Notwithstanding anything to the contrary contained in this Section 2 or elsewhere in this Security Agreement, the parties hereto acknowledge and agree that the security interests granted pursuant to this Security Agreement to Secured Parties and all other rights and benefits afforded hereunder to Secured Parties are expressly subject to the terms and conditions of the Intercreditor Agreement and, in the event of any conflict or inconsistency between the provisions of this Security Agreement and the Intercreditor Agreement, the terms of the Intercreditor Agreement shall prevail. The grants of security interests under Section 2(a) and Section 2(b) constitute two separate and distinct grants of security, and each such security interest shall constitute a security interest separate and apart (and of a different class and claim) from the other security interest. As agreed in the

Intercreditor Agreement, Secured Parties' Liens on any Common Collateral shall be of equal priority.

3. Representations and Warranties. Company represents and warrants to Secured Parties that:

(a) Company is the owner or is the licensee of the Collateral (or, in the case of after-acquired Collateral, at the time Company acquires rights in the Collateral, will be the owner or licensee thereof) and that no other Person has (or, in the case of after-acquired Collateral, at the time Company acquires rights therein, will have) any right, title, claim or interest (by way of Lien or otherwise) in, against or to the Collateral except (i) with respect to Persons granted licenses or sublicenses by Company prior to March 24, 2013 or in the Novvi and IFF Agreements under some or all of such Collateral for certain exclusive and non-exclusive fields of use and activities (collectively, the "**Granted Licenses**"), (ii) with respect to Collateral that is licensed to Company, the owner of such Collateral, and (iii) with respect to Collateral that is non-exclusively licensed to Company, other possible licensees of such Collateral. Schedule A hereto identifies those Persons who have received Granted Licenses that were considered material by Company and disclosed in Company's periodic filings with the Securities and Exchange Commission;

(b) (i) upon the filing of UCC-1 financing statements in the appropriate filing offices, Maxwell has (or in the case of after-acquired Common Collateral, at the time Company acquires rights therein, will have) a first priority perfected security interest in the Common Collateral to the extent that a security interest in the Common Collateral can be perfected by such filing; and (ii) upon the filing of UCC-1 financing statements in the appropriate filing offices, Total has (or in the case of after-acquired Collateral, at the time Company acquires rights therein, will have) a first priority perfected security interest in the Collateral to the extent that a security interest in the Collateral can be perfected by such filing;

(c) as of the Effective Date (or, after giving effect to any update to Schedule A made pursuant to Section 5(c), as of the date of such update), all information set forth in Schedule A hereto is true and correct;

(d) as of the Effective Date (or, after giving effect to any update to Schedule A made pursuant to Section 5(c), as of the date of such update), Company does not own any Patents, trademarks or copyrights registered in, or the subject of pending applications in, the Patent and Trademark Office or the Copyright Office or any similar offices or agencies in any other country or any political subdivision thereof, other than those described on Schedule A hereto;

(e) Company has the sole, full and unencumbered right, title and interest in and to the trademarks shown on Schedule A (other than the Granted Licenses), and the goods and services covered by the registrations thereof, and, to the extent registered, such registrations are, to Company's knowledge, valid and enforceable and in full force and effect;

(f) Company has the sole, full and unencumbered right, title and interest in and to each of the Patents shown on Schedule A (other than the Granted Licenses or the third party

ownership interests in those Patents that are exclusively licensed by Company), and the registrations thereof, to the Company's knowledge, are valid and enforceable and in full force and effect;

(g) Company has the sole, full and unencumbered right, title and interest in and to each of the copyrights shown on Schedule A, and according to the records of the Copyright Office, each of said copyrights is valid and enforceable and in full force and effect;

(h) as of the Effective Date, there is no claim by any third party that any Patents, trademarks or copyrights shown on Schedule A that are necessary in the operation of the Company's business are invalid and unenforceable or do or may violate the rights of any Person;

(i) all licenses of Patents, trademarks, copyrights, and trade secrets which any Person has granted to Company are set forth on Schedule A hereto to the extent required to be disclosed in the Company's periodic filings with the Securities and Exchange Commission;

(j) as of the Effective Date, all of the Total Collateral is identified as such in Schedule A hereto;

(k) Company has obtained from each employee who may be considered the inventor of patentable inventions (invented within the scope of such employee's employment) an assignment to Company of all rights to such inventions, including Patents; and

(l) Company has taken reasonable steps to protect the secrecy and the validity under applicable law of its material trade secrets.

4. General Covenants. Company hereby agrees:

(a) to perform, at the sole expense of Company, all acts that may be necessary or desirable to maintain, preserve, protect and perfect each Secured Party's interest in its Collateral, the Lien granted to such Secured Party therein and the perfection and the first priority of such Lien, including procuring, executing and delivering any notices of security interest for each relevant type of intellectual property in forms reasonably acceptable to such Secured Party and suitable for filing with the Patent and Trademark Office or the Copyright Office, security interests, endorsements, assignments, financing statements and other writings deemed necessary or appropriate by such Secured Party;

(b) not to use or permit any Collateral to be used (i) in violation of any applicable law, rule or regulation, the violation of which could reasonably be expected to result in a material adverse effect on Company or the Collateral, or (ii) in violation of any policy of insurance covering the Collateral;

(c) to pay promptly when due all taxes and other governmental charges, and promptly discharge all governmental Liens now or hereafter imposed upon or affecting any Collateral;

(d) without 30 days' written notice to each Secured Party, (i) not to change Company's name or place of business (or, if Company has more than one place of business, its chief executive office), and (ii) not to change Company's state of incorporation;

(e) to appear in and defend any action or proceeding which may affect adversely its title to or any Secured Party's interest in the Collateral;

(f) to keep accurate and complete records of the Collateral and to provide each Secured Party with such records and such other reports and information relating to the Collateral as such Secured Party may request from time to time;

(g) not to surrender or lose possession of (other than to Secured Parties), sell, encumber, lease, rent, or otherwise dispose of or transfer any Collateral necessary or useful in the operation of Company's business or right or interest therein, and to keep such Collateral free of all Liens other than (i) with concurrent written notice to each Secured Party, licenses and sublicenses under the Collateral that may be granted by Company in the ordinary course of its business to third parties consistent with Company's past practice and (ii) disclosures of non-material trade secrets that may be made by Company during presentations at scientific conferences or in publications in scientific and trade journals in the ordinary course of business consistent with past practice; and

(h) to permit each Secured Party and its representatives the right, at any time during normal business hours, upon reasonable prior notice, to (i) inspect Company's records relating to its Collateral and (ii), with the presence and participation of a Company-designated representative, discuss the Company's affairs and finances with its directors, officers and independent public accountants, in each case, only as necessary or useful to maintain, preserve, protect and perfect the such Secured Party's interest in its Collateral and, in each case, at Company's sole cost and expense.

5. Additional Covenants. Company hereby agrees:

(a) Except to the extent that each Secured Party gives its prior written consent (it being understood that the consent of Maxwell shall not be required for matters solely in respect of the Total Collateral):

(i) Company (either itself or through licensees) will continue to use its trademarks shown on Schedule A that are necessary in the operation of its business in connection with each and every trademark class of goods or services applicable to its current line of products or services as reflected in its current catalogs, brochures, price lists or similar materials in order to maintain such trademarks in full force and effect free from any claim of abandonment for nonuse, and Company will not (and will not permit any licensee thereof to) do any act or knowingly omit to do any act whereby any such trademark may become invalidated;

(ii) Company will not do any act or omit to do any act, the consequence of which may be that any Patent registrations may become abandoned or dedicated to the public domain or the remedies available against potential infringers weakened and shall notify each Secured Party immediately if it knows of any reason or has reason to know that any such Patent

registration may become abandoned or dedicated; however, if each applicable Secured Party does not give consent to Company to abandon a Patent that Company desires to abandon within thirty (30) days after notice to abandon, then such Secured Party will be deemed to have given consent to such abandonment, but if such Secured Party timely responds to not abandon, then such Secured Party will be solely responsible for any further patent prosecution or maintenance costs related to such specific Patent until and unless such Secured Party elects, in its sole discretion, to allow Company to abandon such Patent; and

(iii) Company will not do any act or omit to do any act, the consequence of which may be that any copyrights shown on Schedule A that are necessary for the operation of its business may become abandoned or dedicated to the public domain or the remedies available against potential infringers weakened and shall notify each Secured Party immediately if it knows of any reason or has reason to know that any such copyright may become abandoned or dedicated to the public domain.

(b) Company will promptly (and in any event within ten (10) business days) notify each Secured Party (and shall update Schedule A accordingly) upon the filing, either by Company or through any agent, employee, licensee or designee, of (i) an application for the registration of any Patent or trademark, with the Patent and Trademark Office or any similar office or agency in any other country or any political subdivision thereof, (ii) any assignment of any Patent or trademark, which Company may acquire from a third party, with the Patent and Trademark Office or any similar office or agency in any other country or any political subdivision thereof, or (iii) any assignment of any copyright, which Company may acquire from a third party, with the Copyright Office or any similar office or agency in any other country or any political subdivision thereof. Upon the request of any Secured Party, Company shall execute and deliver any and all agreements, instruments, documents and papers as such Secured Party may request to evidence such Secured Party's security interest in such Patent, trademark (and the goodwill and general intangibles of Company relating thereto or represented thereby), or copyright, and Company authorizes such Secured Party to amend an original counterpart of the applicable notice of security interest executed pursuant to Section 4(a) of this Security Agreement without first obtaining Company's approval of or signature to such amendment and to record such document with the Patent and Trademark Office or Copyright Office, as applicable;

(c) Until the termination of this Security Agreement, Company will provide to each Secured Party an updated Schedule A within five (5) business days after the last day of each month, commencing May 31, 2013. At Company's sole expense, Company shall execute and deliver any and all agreements, instruments, documents and papers consistent with Section 4(a) as such Secured Party may request with regard to the updates to Schedule A.

(d) Prior to the termination of this Security Agreement, Company shall not register or cause to be registered with the Copyright Office any copyright registrations with respect to any proprietary software of Company or any other property that is subject to registration with the Copyright Office; provided, that Company may register or cause to be registered such proprietary software or other property of Company with the Copyright Office if such copyright registration is made in connection with the enforcement against third parties of Company's rights with respect to such proprietary software or other property and (ii) Company provides each Secured Party five (5)

business days prior notice of such copyright registration. Prior to the termination of this Security Agreement, Company shall file or cause to be filed with the Copyright Office a copyright application with respect to any major revisions or upgrades to any proprietary software that has previously been registered by Company with the Copyright Office. Company shall file for such registration within thirty (30) days from such major revision or upgrade and shall notify each Secured Party in writing five (5) business days prior to such filing.

(e) Company will take all necessary steps in any proceeding before the Patent and Trademark Office, the Copyright Office or any similar office or agency in any other country or any political subdivision thereof, to diligently prosecute or maintain, as applicable, each application and registration of the Patents, trademarks, and copyrights shown on Schedule A that are necessary for the operation of its business, including filing of renewals, affidavits of use, affidavits of incontestability and opposition, interference and cancellation proceedings (except to the extent that dedication, abandonment or invalidation is permitted hereunder);

(f) Company shall (i) use proper statutory notice in connection with its use of the Patents, trademarks and copyrights shown on Schedule A, (ii) maintain consistent standards of quality in its manufacture of products sold under the trademarks or provision of services in connection with the trademarks, and (iii) take all reasonable steps necessary to protect the secrecy and the validity under applicable law of all its material trade secrets; it being understood that disclosures of non-material trade secrets made by the Company during presentations at scientific conferences or in publications in scientific and trade journals in the ordinary course of business consistent with past practice will not violate (iii);

(g) Company agrees that if it learns of any use by any Person of any term or design likely to cause confusion with any material trademark shown on Schedule A that is necessary for the operation of its business, Company shall promptly notify each Secured Party of such use and of all steps taken and to be taken to remedy any infringement of any such trademark; and

(h) Company shall maintain with each employee who may have access to the trade secrets of Company an agreement by which such employee agrees not to disclose such trade secrets and with each employee who may be the inventor of patentable inventions (invented within the scope of such employee's employment) an invention assignment agreement requiring such employee to assign all rights to such inventions, including Patents and patent applications, to Company and further requiring such employee to cooperate fully with Company, its successors in interest, including each Secured Party, and their counsel, in the prosecution of any patent application or in any litigation involving the invention, whether such cooperation is required during such employee's employment with Company or after the termination of such employment.

6. Authorized Action by Secured Parties. Company hereby irrevocably appoints each Secured Party as its attorney-in-fact (which appointment is coupled with an interest) and agrees that such Secured Party may perform (but such Secured Party shall not be obligated to and shall incur no liability to Company or any third party for failure so to do) any act which Company is obligated by this Security Agreement to perform, and to exercise such rights and powers as Company might exercise with respect to the Collateral in which such Secured Party has a security interest pursuant to this Security Agreement, including the right to (a) collect by legal proceedings or otherwise and

endorse, receive and receipt for all dividends, interest, payments, proceeds and other sums and property now or hereafter payable on or on account of the Collateral; (b) enter into any extension, reorganization, deposit, merger, consolidation or other agreement pertaining to, or deposit, surrender, accept, hold or apply other property in exchange for the Collateral; (c) make any compromise or settlement, and take any action it deems advisable, with respect to the Collateral; (d) insure, process and preserve the Collateral; (e) pay any indebtedness of Company relating to the Collateral; (f) file notices of the security interest granted hereunder with the Patent and Trademark Office or the Copyright Office, and foreign equivalents of any of the foregoing, and execute other documents, instruments and agreements required hereunder; and (g) file UCC financing statements; provided, however, that no Secured Party shall exercise any such powers granted pursuant to subsections (a) through (e) prior to the occurrence of an Event of Default and shall only exercise such powers during the continuance of an Event of Default. Company agrees to reimburse each Secured Party upon demand for any reasonable costs and expenses, including attorneys' fees, that such Secured Party may incur while acting as Company's attorney-in-fact hereunder, all of which costs and expenses are included in the Obligations. It is further agreed and understood between the parties hereto that such care as each Secured Party gives to the safekeeping of its own property of like kind shall constitute reasonable care of the Collateral when in such Secured Party's possession; provided, however, that no Secured Party shall be required to make any presentment, demand or protest, or give any notice and need not take any action to preserve any rights against any prior party or any other person in connection with the Obligations or with respect to the Collateral. Each Secured Party hereby acknowledges and agrees that it has not and will not submit any filings in respect of the Common Collateral with any foreign equivalents of the U.S. Patent and Trademark Office or the U.S. Copyright Office without giving at least 5 days prior written notice to the other Secured Party (or such shorter period as may be agreed by Secured Parties).

7. Litigation and Other Proceedings.

(a) Company shall have the right to commence and diligently prosecute such suits, proceedings or other actions for infringement or other damage, or reexamination or reissue proceedings, or opposition or cancellation proceedings as are reasonable to protect any of the material Patents, trademarks, copyrights or trade secrets in the Collateral.

(b) Upon the occurrence and during the continuation of an Event of Default, each Secured Party shall have the right but not the obligation to bring suit or institute proceedings in the name of Company or such Secured Party to enforce any rights in the Collateral in which such Secured Party has been granted a security interest pursuant to this Security Agreement, including any license thereunder, in which event Company shall at the request of such Secured Party do any and all lawful acts and execute any and all documents reasonably required by such Secured Party in aid of such enforcement.

8. Default and Remedies.

(a) Remedies. Upon the occurrence and during the continuance of any Event of Default, each Secured Party shall have the rights of a secured party (as defined under the UCC), all rights granted by this Security Agreement and by law, including the right to: (a) require Company to assemble the Collateral in which such Secured Party has been granted a security interest pursuant to

this Security Agreement and make it available to such Secured Party at a place to be designated by such Secured Party; and (b) prior to the disposition of the Collateral, store, process, repair or recondition it or otherwise prepare it for disposition in any manner and to the extent such Secured Party deems appropriate. Company hereby agrees that ten (10) days' notice of any intended sale or disposition of any Collateral is reasonable. In furtherance of each Secured Party's rights hereunder, Company hereby grants to each Secured Party, to the extent not exclusively licensed or sublicensed to another Person, an irrevocable (subject to termination of this Security Agreement), non-exclusive license, exercisable without royalty or other payment by such Secured Party, and exercisable only in connection with the exercise of its remedies hereunder, to use, license or sublicense any Patent, trademark, trade name, copyright or other intellectual property in the Collateral in which such Secured Party has been granted a security interest pursuant to this Security Agreement, together with the right of access to all media in which any of the foregoing may be recorded or stored.

(b) Application of Common Collateral Proceeds. The proceeds and/or avails of the Common Collateral, or any part thereof, and the proceeds and the avails of any remedy hereunder (as well as any other amounts of any kind held by any Secured Party at the time of, or received by any Secured Party after, the occurrence of an Event of Default) in respect of the Common Collateral shall be paid and applied as set forth in Section 2.01 of the Intercreditor Agreement.

(c) Application of Total Collateral Proceeds. The proceeds and/or avails of the Total Collateral, or any part thereof, and the proceeds and the avails of any remedy hereunder in respect of the Total Collateral (as well as any other amounts of any kind held by Total at the time of, or received by Total after, the occurrence of an Event of Default in respect of the Total Collateral) shall be paid and applied as follows:

(i) First, to the payment of reasonable costs and expenses, including all amounts expended to preserve the value of the Total Collateral, of foreclosure or suit, if any, and of such sale and the exercise of any other rights or remedies, and of all proper fees, expenses, liability and advances, including reasonable legal expenses and attorneys' fees, incurred or made hereunder by Total;

(ii) Second, to the payment to Total of the Total Obligations then owing or unpaid to Total (to be applied first to accrued interest and second to outstanding principal); and

(iii) Third, to the payment of the surplus, if any, to Company, its successors and assigns, or to whomsoever may be lawfully entitled to receive the same.

9. Miscellaneous.

(a) Tax Payments. Company shall pay upon demand any stamp or other taxes, levies or charges of any jurisdiction with respect to the execution, delivery, registration, performance and enforcement of this Security Agreement. Upon request by any Secured Party, Company shall furnish evidence satisfactory to such Secured Party that all requisite authorizations and approvals by, and notices to and filings with, governmental authorities and regulatory bodies have been obtained and made and that all requisite taxes, levies and charges have been paid.

(b) Notices. Except as otherwise provided herein, all notices, requests, demands, consents, instructions or other communications to or upon Company or any Secured Party under this Security Agreement shall be in writing and faxed, mailed or delivered to such party to the facsimile number or its address set forth below (or to such other facsimile number or address as the recipient of any notice shall have notified the other in writing). All such notices and communications shall be effective (a) when sent by Federal Express or other overnight service of recognized standing, upon receipt; (b) when mailed, by registered or certified mail, first class postage prepaid and addressed as aforesaid through the United States Postal Service, upon receipt; (c) when delivered by hand, upon delivery; and (d) when faxed, upon confirmation of receipt.

Total: Total Energies Nouvelles Activités USA
24 Cours Michelet
92800 Puteaux
Attn: Bernard Clement
Telephone: + 33 1 4744 4404
Facsimile: +33 1 4135 6582

Maxwell: Maxwell (Mauritius) Pte Ltd
60B Orchard Road #06-18
Tower 2, The Atrium @ Orchard
Singapore 238891
Attn: Managing Member
Facsimile: (65) 6821-1188
Email: enquiry@temasek.com.sg

Company: Amyris, Inc.
5885 Hollis Street, Suite 100
Emeryville, CA 94608
Attn: General Counsel
Telephone: (510) 450-0761
Facsimile: (510) 225-2645

(c) Termination of Security Interest and Security Agreement. Upon the earlier of (i) payment in full of all Obligations and (ii) the Security Release Date, this Security Agreement, the security interest granted herein, and each Secured Party's rights and Company's obligations under the 2012 Letter Agreement and the 2013 Letter Agreement with regard to any security interest shall terminate and all rights to the Collateral shall revert to Company. Upon such termination each Secured Party hereby authorizes Company to file any UCC termination statements necessary to effect such termination, and each Secured Party will, at Company's expense, promptly (but in any event within 5 business days of Company's request therefor) execute and deliver to Company any additional documents or instruments as Company shall reasonably request to evidence such termination (including, without limitation, a termination letter substantially in the form attached hereto as Exhibit A and the preparation of documents necessary for the termination of any filings made with the Patent and Trademark Office or the Copyright Office) and Company shall also be solely responsible for reasonable, duly documented fees and expenses incurred or payable in connection with the termination of such filings made by any Secured Party with the Patent and

Trademark Office or the Copyright Office. As used herein, “**Security Release Date**” means the later of (i) the date on which Maxwell receives written confirmation from Total and Company that they have entered into Final Documentation regarding the Establishment of a JVCO and such documentation has become effective and (ii) the first date on which any 2013 Notes have been issued to Maxwell (it being understood that this definition of Security Release Date shall supersede anything to the contrary in the 2012 Letter Agreement or the 2013 Letter Agreement). As used in the above definition, “**Final Documentation regarding Establishment of a JVCO**” means the Interim Shareholders’ Agreement between Total, Company and NCO, the License Agreement between Total and JVCO and the Total’s and Company’s Subscription Agreements with JVCO.

(d) Nonwaiver. No failure or delay on any Secured Party’s part in exercising any right hereunder shall operate as a waiver thereof or of any other right nor shall any single or partial exercise of any such right preclude any other further exercise thereof or of any other right.

(e) Amendments and Waivers. This Security Agreement may not be amended or modified, nor may any of its terms be waived, except by written instruments signed by Company and each Secured Party; provided that the consent of Maxwell shall not be required for any amendment, modification or waiver of this Security Agreement which does not relate to or in any way adversely affect the Maxwell Obligations or the Common Collateral. Each waiver or consent under any provision hereof shall be effective only in the specific instances for the purpose for which given.

(f) Assignments. This Security Agreement shall be binding upon and inure to the benefit of each Secured Party and Company and their respective successors and assigns; provided, however, that Company may not sell, assign or delegate rights and obligations hereunder without the prior written consent of each Secured Party.

(g) Cumulative Rights, etc. The rights, powers and remedies of each Secured Party under this Security Agreement shall be in addition to all rights, powers and remedies given to such Secured Party by virtue of any applicable law, rule or regulation of any governmental authority, or any other agreement, all of which rights, powers, and remedies shall be cumulative and may be exercised successively or concurrently without impairing such Secured Party’s rights hereunder. Company waives any right to require any Secured Party to proceed against any person or entity or to exhaust any Collateral or to pursue any remedy in such Secured Party’s power.

(h) Partial Invalidity. If at any time any provision of this Security Agreement is or becomes illegal, invalid or unenforceable in any respect under the law of any jurisdiction, neither the legality, validity or enforceability of the remaining provisions of this Security Agreement nor the legality, validity or enforceability of such provision under the law of any other jurisdiction shall in any way be affected or impaired thereby.

(i) Expenses. Company shall pay on demand all reasonable fees and expenses, including reasonable attorneys’ fees and expenses, incurred by each Secured Party in connection with custody, preservation or sale of, or other realization on, any of the Collateral or the enforcement or attempt to enforce any of the Obligations which is not performed as and when required by this Security Agreement.

(j) Construction. This Security Agreement is the result of negotiations among, and has been reviewed by, Company, Secured Parties and their respective counsel. Accordingly, this Security Agreement shall be deemed to be the product of all parties hereto, and no ambiguity shall be construed in favor of or against Company or any Secured Party.

(k) Filings. Each Secured Party has the right to file documents, e.g., UCC-1 filings and documents with the Patent and Trademark Office or the Copyright Office, as it deems necessary or desirable to maintain, preserve, protect and perfect such Secured Party's security interest in the Collateral, the Lien granted to such Secured Party therein and the perfection and first priority of such Lien.

(l) Entire Agreement. This Security Agreement and the other Loan Documents constitute and contain the entire agreement of Company and Secured Parties with respect to the subject matter of this Security Agreement and supersede any and all prior agreements, negotiations, correspondence, understandings and communications among the parties, whether written or oral, respecting the subject matter hereof. For clarity, nothing in this Security Agreement shall limit or otherwise diminish any license or other rights of any Secured Party in or to any Intellectual Property of the Company whether granted in the Collaboration Agreement and/or any other written agreement entered into by the parties hereto.

(m) Other Interpretive Provisions. References in this Security Agreement to any document, instrument or agreement (a) includes all exhibits, schedules and other attachments thereto, (b) includes all documents, instruments or agreements issued or executed in replacement thereof, and (c) means such document, instrument or agreement, or replacement or predecessor thereto, as amended, modified and supplemented from time to time and in effect at any given time. The words "hereof," "herein" and "hereunder" and words of similar import when used in this Security Agreement refer to this Security Agreement as a whole and not to any particular provision of this Security Agreement. The words "include" and "including" and words of similar import when used in this Security Agreement shall not be construed to be limiting or exclusive.

(n) Amendment and Restatement. This Security Agreement amends and restates in its entirety the Original Security Agreement. Nothing contained herein shall be construed as a release or discharge of the security interests or Liens granted by Company to Total under the Original Security Agreement, and the security interests and Liens granted by Company to Total under the Original Security Agreement continue without interruption under this Security Agreement to secure the Obligations and such security interests and Liens are hereby reaffirmed, ratified and confirmed in all respects. Nothing herein shall be construed as a substitution, novation, discharge or release of the obligations or liabilities outstanding under the Original Security Agreement, which shall remain in full force and effect.

(o) Governing Law; Jurisdiction. (i) This Security Agreement shall be governed by and construed in accordance with the laws of the State of California without reference to conflicts of law rules (except to the extent governed by the UCC).

(ii) Each Secured Party and Company hereby irrevocably and unconditionally submits, for itself and its property, to the nonexclusive jurisdiction of the courts of the State of

California sitting in the City and County of San Francisco, California, and of the United States District Court for the Northern District of California, and any appellate court from any thereof, in any action or proceeding arising out of or relating to this Security Agreement, or for recognition or enforcement of any judgment, and each of the parties hereto hereby irrevocably and unconditionally agrees that all claims in respect of any such action or proceeding may be heard and determined in such California State or, to the extent permitted by law, in such Federal court. Each of the parties hereto agrees that a final judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law. Nothing in this Security Agreement shall affect any right that either Secured Party may otherwise have to bring any action or proceeding relating to this Security Agreement or any other Loan Document against Company or its properties in the courts of any jurisdiction.


(iii) Each Secured Party and Company hereby irrevocably and unconditionally waives, to the fullest extent it may legally and effectively do so, any objection which it may now or hereafter have to the laying of venue of any suit, action or proceeding arising out of or relating to this Security Agreement or any other Loan Document in any court referred to in paragraph (ii) of this Section. Each of the parties hereto hereby irrevocably waives, to the fullest extent permitted by law, the defense of an inconvenient forum to the maintenance of such action or proceeding in any such court.

(p) Counterparts. This Security Agreement may be executed in any number of counterparts, each of which shall be an original, but all of which together shall be deemed to constitute one instrument, it being understood that all parties need not sign the same counterpart. Any such counterpart, to the extent delivered by electronic delivery, shall be treated in all manner and respects as an original executed counterpart and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered in person. No party shall raise the use of electronic delivery to deliver a signature, or the fact that any signature or agreement or instrument was transmitted or communicated through the use of electronic delivery, as a defense to the formation of a contract, and each party forever waives any such defense, except to the extent such defense relates to lack of authenticity.

[The remainder of this page is intentionally left blank]

IN WITNESS WHEREOF, Company has caused this Security Agreement to be executed effective as of the Effective Date.

AMYRIS, INC.

By:  _____

Name: _____

Title: _____

AGREED:

TOTAL ENERGIES NOUVELLES ACTIVITES USA,
as Secured Party

By: _____

Name: _____

Title: _____

MAXWELL (MAURITIUS) PTE LTD,
as Secured Party

By: _____

Name: _____

Title: _____

IN WITNESS WHEREOF, Company has caused this Security Agreement to be executed effective as of the Effective Date.

AMYRIS, INC.

By: _____

Name: _____

Title: _____

AGREED:

TOTAL ENERGIES NOUVELLES ACTIVITES USA,
as Secured Party

By: _____

Name: Richard CRENEAU

Title: President

MAXWELL (MAURITIUS) PTE LTD,
as Secured Party

By: _____

Name: _____

Title: _____

IN WITNESS WHEREOF, Company has caused this Security Agreement to be executed effective as of the Effective Date.

AMYRIS, INC.

By: _____

Name: _____

Title: _____

AGREED:

TOTAL ENERGIES NOUVELLES ACTIVITES USA,
as Secured Party

By: _____

Name: _____

Title: _____

MAXWELL (MAURITIUS) PTE LTD,
as Secured Party

By: _____ 

Name: CHIA SONG HWEE

Title: Authorised Signatory

ATTACHMENT 1
TO SECURITY AGREEMENT
(Common Collateral)

All right, title, interest, claims and demands of Company in and to all Intellectual Property now or hereafter owned or licensed by the Company and to the extent not otherwise included, all Proceeds (as defined in the UCC) and products of the foregoing, and all accessions to, substitutions and replacements for, and rents and profits of each of the foregoing. Notwithstanding anything herein to the contrary, in no event shall the security interest granted hereunder attach to, and the Common Collateral shall not include, (A) any Intellectual Property of the Company to the extent that and for so long as the grant of a security interest therein is (1) prohibited by any applicable law, rule, regulation, statute or order of any governmental authority, or (2) would result in a violation, breach or default under any contract entered into by the Company and a third party that is in effect as of March 24, 2013 or under the Novvi and IFF Agreements, (B) any Intellectual Property acquired or licensed from a third party after March 24, 2013, to the extent that and for so long as the grant of a security interest therein would result in a violation, breach or default under the contract entered into by the Company and such third party regarding such Intellectual Property or (C) any Total Collateral.

As used above, the term “**Intellectual Property**” means all intellectual and similar property of every kind and nature, including inventions, designs, Patents (whether registered or unregistered), copyrights (whether registered or unregistered), trademarks (whether registered or unregistered), trade secrets, domain names, confidential or proprietary technical and business information, know-how, methods, processes, drawings, specifications or other data or information and all memoranda, notes and records with respect to any research and development, software and databases and all embodiments or fixations thereof whether in tangible or intangible form or contained on magnetic media readable by machine together with all such magnetic media and related documentation, and all additions; improvements and accessions to, and books and records necessary to describe any of the foregoing.

ATTACHMENT 2
TO SECURITY AGREEMENT
(Total Collateral)

All right, title, interest, claims and demands of Company in and to the following Patents (including any Patents issued in respect of any patent applications) and to the extent not otherwise included, all Proceeds (as defined in the UCC) and products of the foregoing, and all accessions to, substitutions and replacements for, and rents and profits of each of the foregoing:

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
AM-800	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	Neil S. Renninger Derek J. McPhee	US 11/869,673	10/09/07	US 2008/0098645	05/01/08	US 7,399,323	07/15/08
AM-800 PCT	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	Neil S. Renninger Derek J. McPhee	PCT/US2007/02189 0	10/10/07	WO 2008/045555	04/17/08		
AM-800 AU	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	Neil S. Renninger Derek J. McPhee	AU 2007308137				AU 2007308137	07/14/11
AM-800 BR	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	Neil S. Renninger Derek J. McPhee	BR PI0719659-8					

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
AM-800 CA	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	Neil S. Renninger Derek J. McPhee	CA 2,665,198					
AM-800 CN	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	Neil S. Renninger Derek J. McPhee	CN 200780045575.3		CN101553558A	10/07/09		
AM-800 CO	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	Neil S. Renninger Derek J. McPhee	CO 09040600		CO 617	6/18/10 ⁰		
AM-800 EP	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	Neil S. Renninger Derek J. McPhee	EP 07839526.6		EP 2084249	08/05/09		
AM-800 GT	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	Neil S. Renninger Derek J. McPhee	GT A-2009-0078					
AM-800 HK	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	Neil S. Renninger Derek J. McPhee	HK 09107399.3		HK 1127510	08/25/09		

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
AM-800 HN	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	Neil S. Renninger Derek J. McPhee	HN 2009-000616				HN 5123, Folio 75, vol XII	11/29/11
AM-800 ID	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	Neil S. Renninger Derek J. McPhee	ID W-00200901237		ID 049.2982 A	08/20/09		
AM-800 IN	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	Neil S. Renninger Derek J. McPhee	IN 2382/CHENP/2009					
AM-800 JP	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	Neil S. Renninger Derek J. McPhee	JP 2009-532447		JP 2010-506037A	02/25/10		
AM-800 KR	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	Neil S. Renninger Derek J. McPhee	KR 10-2009-7009520		KR 10-2009-0079926	07/22/09		
AM-800 MX	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	Neil S. Renninger Derek J. McPhee	MX/a/2009/003715				MX 285041	3/25/11 ⁰

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
AM-800 MY	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	Neil S. Renninger Derek J. McPhee	MY PI20091396				MY 145076-A	12/15/11
AM-800 MZ	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	Neil S. Renninger Derek J. McPhee	MZ 152/2009					
AM-800 NI	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	Neil S. Renninger Derek J. McPhee	NI 2009-000047		NI Gazette No. 21	02/01/10	NI 2068 RPI	10/27/11
AM-800 SG	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	Neil S. Renninger Derek J. McPhee	SG 200902252-6				SG 151535	7/31/12 ⁰
AM-800 SV	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	Neil S. Renninger Derek J. McPhee	SV E-3208/2009 P-7776					
AM-800 TT	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	Neil S. Renninger Derek J. McPhee	TT/A/2009/00087					

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
AM-800 VN	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	Neil S. Renninger Derek J. McPhee	VN 1-2009-00933				VN 11469	06/10/13
AM-800 ZA	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	Neil S. Renninger Derek J. McPhee	ZA 2009/02205				ZA 2009/02205	09/29/10
AM-801	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	Neil S. Renninger Derek J. McPhee	US 11/973,901	10/09/07	US 2008/0083158	04/10/08	US 7,846,222	12/07/10

SCHEDULE A
TO SECURITY AGREEMENT

SCHEDULE A TO AMENDED AND RESTAED INTELLECTUAL PROPERTY SECURITY AGREEMENT

I. Amyris Owned Patents and Patent Applications

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
AM-400	Fuel Components, Fuel Compositions and Methods of Making and Using the Same	Neil S. Renninger Jack D. Newman Keith Kinkead Reiling	US 11/753,586	05/25/07	US 2008/0092829	04/24/08	US 7,854,774	12/21/10
AM-400 PCT	Fuel Components, Fuel Compositions and Methods of Making and Using the Same	Neil S. Renninger Jack D. Newman Keith Kinkead Reiling	PCT/US2007/012468	05/25/07	WO 2007/139925	12/06/07		
AM-400 AU	Fuel Components, Fuel Compositions and Methods of Making and Using the Same	Neil S. Renninger Jack D. Newman Keith Kinkead Reiling	AU 2007267914	11/26/08			AU 2007267914	05/31/12
AM-400 BR	Fuel Components, Fuel Compositions and Methods of Making and Using the Same	Neil S. Renninger Jack D. Newman Keith Kinkead Reiling	BR PI0712160-1					
AM-400 CA	Fuel Components, Fuel Compositions and Methods of Making and Using the Same	Neil S. Renninger Jack D. Newman Keith Kinkead Reiling	CA 2,652,732					
AM-400 EP	Fuel Components, Fuel Compositions and Methods of Making and Using the Same	Neil S. Renninger Jack D. Newman Keith Kinkead Reiling	EP 7777279.6		EP 2038530	03/25/09		
AM-400 IN	Fuel Components, Fuel Compositions and Methods of Making and Using the Same	Neil S. Renninger Jack D. Newman Keith Kinkead Reiling	IN 7178/CHENP/2008					
AM-400 JP	Fuel Components, Fuel Compositions and Methods of Making and Using the Same	Neil S. Renninger Jack D. Newman Keith Kinkead Reiling	JP 2009-512161		JP 2009-538373A	11/05/09	JP 4,630,940	11/19/10

As of: September 27, 2013

*Indicates Total Collateral.

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
AM-400 ZA	Fuel Components, Fuel Compositions and Methods of Making and Using the Same	Neil S. Renninger Jack D. Newman Keith Kinkead Reiling	ZA 2008/09955				ZA 2008/09955	03/31/10
AM-500	Production of Isoprenoids	Neil S. Renninger Jack D. Newman Keith Kinkead Reiling Rika Regentin Christopher J. Paddon	US 11/754,235	05/25/07	US 20080274523	11/06/08	US 7,659,097	02/09/10
AM-500 C2	Production of Isoprenoids	Neil S. Renninger Jack D. Newman Keith Kinkead Reiling Rika Regentin Christopher J. Paddon	US 13/848,045	03/20/13	US 2013/0252295	9/26/13		
AM-500 PCT	Production of Isoprenoids	Neil S. Renninger Jack D. Newman Keith Kinkead Reiling Rika Regentin Christopher J. Paddon	PCT/US2007/069807	05/25/07	WO 2007/140339	12/06/07		
AM-500 AU	Production of Isoprenoids	Neil S. Renninger Jack D. Newman Keith Kinkead Reiling Rika Regentin Christopher J. Paddon	AU 2007267033				AU 2007267033	09/06/12
AM-500 AU D1	Production of Isoprenoids	Neil S. Renninger Jack D. Newman Keith Kinkead Reiling Rika Regentin Christopher J. Paddon	AU 2012202630	05/04/12				
AM-500 BR	Production of Isoprenoids	Neil S. Renninger Jack D. Newman Keith Kinkead Reiling Rika Regentin Christopher J. Paddon	BR P10713105-4					

As of: September 27, 2013

*Indicates Total Collateral.

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
AM-500 CA	Production of Isoprenoids	Neil S. Renninger Jack D. Newman Keith Kinkead Reiling Rika Regentin Christopher J. Paddon	CA 2,651,747					
AM-500 CN	Production of Isoprenoids	Neil S. Renninger Jack D. Newman Keith Kinkead Reiling Rika Regentin Christopher J. Paddon	CN 200780019353.4		CN 101484584A	07/15/09	CN ZL200780019353.4	03/27/13
AM-500 CO	Production of Isoprenoids	Neil S. Renninger Jack D. Newman Keith Kinkead Reiling Rika Regentin Christopher J. Paddon	CO 08-125171					
AM-500 EP	Production of Isoprenoids	Neil S. Renninger Jack D. Newman Keith Kinkead Reiling Rika Regentin Christopher J. Paddon	EP 07797800.5		EP 2024504	02/18/09		
AM-500 GT	Production of Isoprenoids	Neil S. Renninger Jack D. Newman Keith Kinkead Reiling Rika Regentin Christopher J. Paddon	GT A 2008-0262					
AM-500 HN	Production of Isoprenoids	Neil S. Renninger Jack D. Newman Keith Kinkead Reiling Rika Regentin Christopher J. Paddon	HN 2008-001756		HN 2008-001756	11/14/11	HN 5188, Folio 140, Vol XII	03/22/12
AM-500 HN D1	Production of Isoprenoids	Neil S. Renninger Jack D. Newman Keith Kinkead Reiling Rika Regentin Christopher J. Paddon	HN 2011-000912		HN 2011-000912	11/14/11	HN 5189, Folio 141, Vol XII	03/22/12

As of: September 27, 2013

*Indicates Total Collateral.

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
AM-500 ID	Production of Isoprenoids	Neil S. Renninger Jack D. Newman Keith Kinkead Reiling Rika Regentin Christopher J. Paddon	ID W00200803779		ID 049.1319	04/16/09		
AM-500 IN	Production of Isoprenoids	Neil S. Renninger Jack D. Newman Keith Kinkead Reiling Rika Regentin Christopher J. Paddon	IN 9907/DELNP/2008					
AM-500 KR	Production of Isoprenoids	Neil S. Renninger Jack D. Newman Keith Kinkead Reiling Rika Regentin Christopher J. Paddon	KR 10-2012-7011520					
AM-500 KR D1	Production of Isoprenoids	Neil S. Renninger Jack D. Newman Keith Kinkead Reiling Rika Regentin Christopher J. Paddon	KR 10-2008-7029580	05/03/12				
AM-500 MX	Production of Isoprenoids	Neil S. Renninger Jack D. Newman Keith Kinkead Reiling Rika Regentin Christopher J. Paddon	MX/a/2008/014909				MX 284139	02/18/11
AM-500 MX D1	Production of Isoprenoids	Neil S. Renninger Jack D. Newman Keith Kinkead Reiling Rika Regentin Christopher J. Paddon	MX/a/2011/001857					
AM-500 MY	Production of Isoprenoids	Neil S. Renninger Jack D. Newman Keith Kinkead Reiling Rika Regentin Christopher J. Paddon	MY PI20084571				MY 146612-A	09/14/12

As of: September 27, 2013

*Indicates Total Collateral.

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
AM-500 MZ	Production of Isoprenoids	Neil S. Renninger Jack D. Newman Keith Kinkead Reiling Rika Regentin Christopher J. Paddon	MZ 146/2008				MZ 146/2008	08/24/11
AM-500 NI	Production of Isoprenoids	Neil S. Renninger Jack D. Newman Keith Kinkead Reiling Rika Regentin Christopher J. Paddon	NI 2008-0003111					
AM-500 NI D1	Production of Isoprenoids	Neil S. Renninger Jack D. Newman Keith Kinkead Reiling Rika Regentin Christopher J. Paddon	NI 2008-0003111-I					
AM-500 SG	Production of Isoprenoids	Neil S. Renninger Jack D. Newman Keith Kinkead Reiling Rika Regentin Christopher J. Paddon	SG 200808367-7				SG 147734	08/31/11
AM-500 SG D1	Production of Isoprenoids	Neil S. Renninger Jack D. Newman Keith Kinkead Reiling Rika Regentin Christopher J. Paddon	SG 201103888-2		SG 172646	07/28/11		
AM-500 SV	Production of Isoprenoids	Neil S. Renninger Jack D. Newman Keith Kinkead Reiling Rika Regentin Christopher J. Paddon	SV 2008-003104				No. 14, Book 4 (Folio 029-030)	02/23/11
AM-500 SV D1	Production of Isoprenoids	Neil S. Renninger Jack D. Newman Keith Kinkead Reiling Rika Regentin Christopher J. Paddon	SV 2011-003865		No. 106, Vol 391	06/06/11		

As of: September 27, 2013

*Indicates Total Collateral.

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
AM-500 TT	Production of Isoprenoids	Neil S. Renninger Jack D. Newman Keith Kinkead Reiling Rika Regentin Christopher J. Paddon	TT/A/2008/00241					
AM-500 VN	Production of Isoprenoids	Neil S. Renninger Jack D. Newman Keith Kinkead Reiling Rika Regentin Christopher J. Paddon	VN 1-2008-02948				VN 9835	11/16/11
AM-500 VN D1	Production of Isoprenoids	Neil S. Renninger Jack D. Newman Keith Kinkead Reiling Rika Regentin Christopher J. Paddon	VN 1-2011-02981	11/02/11				
AM-500 ZA	Production of Isoprenoids	Neil S. Renninger Jack D. Newman Keith Kinkead Reiling Rika Regentin Christopher J. Paddon	ZA 2008/09621				ZA 2001/09621	04/28/11
AM-700	Apparatus for Making a Bio-Organic Compound	Neil S. Renninger	US 11/807,048	05/25/07				
AM-700 PCT	Apparatus for Making a Bio-Organic Compound	Neil S. Renninger	PCT/US2007/012467	05/25/07	WO 2007/139924	12/06/07		
AM-700 AU	Apparatus for Making a Bio-Organic Compound	Neil S. Renninger	AU 2007267913		AU 2007267913	05/09/13		
AM-700 BR	Apparatus for Making a Bio-Organic Compound	Neil S. Renninger	BR PI0712508-9					
AM-700 CA	Apparatus for Making a Bio-Organic Compound	Neil S. Renninger	CA 2,652,801					
AM-700 CN	Apparatus for Making a Bio-Organic Compound	Neil S. Renninger	CN 200780028412.4		CN 101495641	07/29/09		
AM-700 CO	Apparatus for Making a Bio-Organic Compound	Neil S. Renninger	CO 08135061		CO 611	12/31/09		

As of: September 27, 2013

*Indicates Total Collateral.

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
AM-700 EP	Apparatus for Making a Bio-Organic Compound	Neil S. Renninger	EP 07777278.8		EP 2021486	02/11/09		
AM-700 HK	Apparatus for Making a Bio-Organic Compound	Neil S. Renninger	HK 09102854.2		HK 1122595	05/22/09		
AM-700 HN	Apparatus for Making a Bio-Organic Compound	Neil S. Renninger	HN 2008-001755				HN 5027	05/25/11
AM-700 ID	Apparatus for Making a Bio-Organic Compound	Neil S. Renninger	ID W00200803809		ID 0491316A	04/16/09		
AM-700 IN	Apparatus for Making a Bio-Organic Compound	Neil S. Renninger	IN 7175/CHENP/2008					
AM-700 JP D1	Apparatus for Making a Bio-Organic Compound	Neil S. Renninger	JP 2013-021938	02/07/13				
AM-700 KR	Apparatus for Making a Bio-Organic Compound	Neil S. Renninger	KR 10-2008-7031413					
AM-700 MX	Apparatus for Making a Bio-Organic Compound	Neil S. Renninger	MX/a/2008/014970				MX 293430	12/09/11
AM-700 MY	Apparatus for Making a Bio-Organic Compound	Neil S. Renninger	MY PI20084768					
AM-700 MZ	Apparatus for Making a Bio-Organic Compound	Neil S. Renninger	MZ 145/2008					
AM-700 NI	Apparatus for Making a Bio-Organic Compound	Neil S. Renninger	NI 2008-000310-I					
AM-700 SG	Apparatus for Making a Bio-Organic Compound	Neil S. Renninger	SG 200808725-6				SG 148288	06/30/11
AM-700 SV	Apparatus for Making a Bio-Organic Compound	Neil S. Renninger	SV E-3107/2008					
AM-700 TT	Apparatus for Making a Bio-Organic Compound	Neil S. Renninger	TT/A/2008/00249					
AM-700 VN	Apparatus for Making a Bio-Organic Compound	Neil S. Renninger	VN 1-2008-03155					
AM-700 ZA	Apparatus for Making a Bio-Organic Compound	Neil S. Renninger	ZA 2008/09957				ZA 2008/09957	08/10/10

As of: September 27, 2013

*Indicates Total Collateral.

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
AM-800*	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	Neil S. Renninger Derek J. McPhee	US 11/869,673	10/09/07	US 2008/0098645	05/01/08	US 7,399,323	07/15/08
AM-800 PCT*	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	Neil S. Renninger Derek J. McPhee	PCT/US2007/021890	10/10/07	WO 2008/045555	04/17/08		
AM-800 AU*	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	Neil S. Renninger Derek J. McPhee	AU 2007308137				AU 2007308137	07/14/11
AM-800 BR*	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	Neil S. Renninger Derek J. McPhee	BR PI0719659-8					
AM-800 CA*	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	Neil S. Renninger Derek J. McPhee	CA 2,665,198					
AM-800 CN*	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	Neil S. Renninger Derek J. McPhee	CN 200780045575.3		CN101553558A	10/07/09		

As of: September 27, 2013

*Indicates Total Collateral.

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
AM-800 CO*	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	Neil S. Renninger Derek J. McPhee	CO 09040600		CO 617	06/18/10		
AM-800 EP*	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	Neil S. Renninger Derek J. McPhee	EP 07839526.6		EP 2084249	08/05/09		
AM-800 GT*	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	Neil S. Renninger Derek J. McPhee	GT A-2009-0078					
AM-800 HK*	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	Neil S. Renninger Derek J. McPhee	HK 09107399.3		HK 1127510	08/25/09		
AM-800 HN*	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	Neil S. Renninger Derek J. McPhee	HN 2009-000616				HN 5123, Folio 75, vol XII	11/29/11
AM-800 ID*	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	Neil S. Renninger Derek J. McPhee	ID W-00200901237		ID 049.2982 A	08/20/09		

As of: September 27, 2013

*Indicates Total Collateral.

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
AM-800 IN*	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	Neil S. Renninger Derek J. McPhee	IN 2382/CHENP/2009					
AM-800 JP*	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	Neil S. Renninger Derek J. McPhee	JP 2009-532447		JP 2010-506037A	02/25/10		
AM-800 KR*	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	Neil S. Renninger Derek J. McPhee	KR 10-2009-7009520		KR 10-2009-0079926	07/22/09		
AM-800 MX*	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	Neil S. Renninger Derek J. McPhee	MX/a/2009/003715				MX 285041	03/25/11
AM-800 MY*	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	Neil S. Renninger Derek J. McPhee	MY PI20091396				MY 145076-A	12/15/11
AM-800 MZ*	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	Neil S. Renninger Derek J. McPhee	MZ 152/2009					

As of: September 27, 2013

*Indicates Total Collateral.

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
AM-800 NI*	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	Neil S. Renninger Derek J. McPhee	NI 2009-000047		NI Gazette No. 21	02/01/10	NI 2068 RPI	10/27/11
AM-800 SG*	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	Neil S. Renninger Derek J. McPhee	SG 200902252-6				SG 151535	07/31/12
AM-800 SV*	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	Neil S. Renninger Derek J. McPhee	SV E-3208/2009 P-7776					
AM-800 TT*	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	Neil S. Renninger Derek J. McPhee	TT/A/2009/00087					
AM-800 VN*	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	Neil S. Renninger Derek J. McPhee	VN 1-2009-00933				VN 11469	06/10/13
AM-800 ZA*	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	Neil S. Renninger Derek J. McPhee	ZA 2009/02205				ZA 2009/02205	09/29/10

As of: September 27, 2013

*Indicates Total Collateral.

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
AM-801*	Fuel Compositions Comprising Farnesane and Farnesane Derivatives and Method of Making and Using the Same	Neil S. Renninger Derek J. McPhee	US 11/973,901	10/09/07	US 2008/0083158	04/10/08	US 7,846,222	12/07/10
AM-900	Jet Fuel Compositions and Methods of Making and Using the Same	Neil S. Renninger Jason Ryder Karl Fisher	US 11/986,484	11/20/07	US 2010/0281845	11/11/10	US 7,942,940	05/17/11
AM-900 PCT	Jet Fuel Compositions and Methods of Making and Using the Same	Neil S. Renninger Jason Ryder Karl Fisher	PCT/US2007/024266	11/20/07	WO 2008/140492	11/20/08		
AM-900 AU	Jet Fuel Compositions and Methods of Making and Using the Same	Neil S. Renninger Jason Ryder Karl Fisher	AU 2007353411				AU 2007353411	12/01/11
AM-900 BR	Jet Fuel Compositions and Methods of Making and Using the Same	Neil S. Renninger Jason Ryder Karl Fisher	BR PI0718978-8					
AM-900 CA	Jet Fuel Compositions and Methods of Making and Using the Same	Neil S. Renninger Jason Ryder Karl Fisher	CA 2,670,307				CA 2,670,307	06/25/13
AM-900 CN	Jet Fuel Compositions and Methods of Making and Using the Same	Neil S. Renninger Jason Ryder Karl Fisher	CN 200780050238.3		CN101636474A	01/27/10		
AM-900 EP	Jet Fuel Compositions and Methods of Making and Using the Same	Neil S. Renninger Jason Ryder Karl Fisher	EP 07874138.6		EP 2099883	09/16/09		
AM-900 IN	Jet Fuel Compositions and Methods of Making and Using the Same	Neil S. Renninger Jason Ryder Karl Fisher	IN 3604/CHENP/2009					
AM-900 ZA	Jet Fuel Compositions and Methods of Making and Using the Same	Neil S. Renninger Jason Ryder Karl Fisher	ZA 2009/03365				ZA 2009/03365	08/25/10
AM-1000	Fuel Compositions Comprising Tetramethylcyclohexane	Jason Ryder Karl Fisher	US 12/175,468	07/18/08	US 2009/0020090	01/22/09	US 7,540,888	06/02/09

As of: September 27, 2013

*Indicates Total Collateral.

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
AM-1000 PCT	Fuel Compositions Comprising Tetramethylcyclohexane	Jason Ryder Karl Fisher	PCT/US2008/008747	07/17/08	WO 2009/014636	01/29/09		
AM-1000 AU	Fuel Compositions Comprising Tetramethylcyclohexane	Jason Ryder Karl Fisher	AU 2008279775				AU 2008279775	01/03/13
AM-1000 BR	Fuel Compositions Comprising Tetramethylcyclohexane	Jason Ryder Karl Fisher	BR PI0814281-5					
AM-1000 CA	Fuel Compositions Comprising Tetramethylcyclohexane	Jason Ryder Karl Fisher	CA 2,694,982					
AM-1000 CN	Fuel Compositions Comprising Tetramethylcyclohexane	Jason Ryder Karl Fisher	CN 200880108232.1		CN 101802136A	08/11/10	CA 2,694,982	06/25/13
AM-1000 EP	Fuel Compositions Comprising Tetramethylcyclohexane	Jason Ryder Karl Fisher	EP 08794558.0		EP 2173837	04/14/10		
AM-1000 IN	Fuel Compositions Comprising Tetramethylcyclohexane	Jason Ryder Karl Fisher	IN 0878/CHENP/2010					
AM-1000 JP	Fuel Compositions Comprising Tetramethylcyclohexane	Jason Ryder Karl Fisher	JP 2010-517017		JP 2010-534251A	11/04/10		
AM-1000 KR	Fuel Compositions Comprising Tetramethylcyclohexane	Jason Ryder Karl Fisher	KR 10-2010-7003628					
AM-1000 MX	Fuel Compositions Comprising Tetramethylcyclohexane	Jason Ryder Karl Fisher	MX/a/2010/000567				MX 283608	02/03/11
AM-1000 ZA	Fuel Compositions Comprising Tetramethylcyclohexane	Jason Ryder Karl Fisher	ZA 2010/00277				ZA 2010/00277	05/25/11
AM-1001	Fuel Compositions Comprising Tetramethylcyclohexane	Jason Ryder Karl Fisher	US 12/175,465	07/18/08	US 2009/0020089	01/22/09	US 7,806,944	10/05/10

As of: September 27, 2013

*Indicates Total Collateral.

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
AM-1100 PCT	DXP Production of Isoprenoids	Larry Anthony Jack Newman	PCT/US2008/060199	04/14/08	WO 2008/128159	10/23/08		
AM-1200	Jet Fuel Compositions and Methods for Making and Using the Same	Neil Renninger Jason Ryder Karl Fisher	US 11/986,485	11/20/07	US 2010/0281846	11/11/10	US 7,935,156	05/03/11
AM-1200 PCT	Jet Fuel Compositions and Methods for Making and Using the Same	Neil Renninger Jason Ryder Karl Fisher	PCT/US2007/024270	11/20/07	WO 2008/133658	01/08/09		
AM-1200 AU	Jet Fuel Compositions and Methods for Making and Using the Same	Neil Renninger Jason Ryder Karl Fisher	AU 2007352386				AU 2007352386	01/25/12
AM-1200 BR	Jet Fuel Compositions and Methods for Making and Using the Same	Neil Renninger Jason Ryder Karl Fisher	BR PI0718973-7					
AM-1200 CA	Jet Fuel Compositions and Methods for Making and Using the Same	Neil Renninger Jason Ryder Karl Fisher	CA 2,670,280					
AM-1200 CN	Jet Fuel Compositions and Methods for Making and Using the Same	Neil Renninger Jason Ryder Karl Fisher	CN 200780050177.0		CN 101589130A	11/25/09	CN ZL200780050177.0	04/17/13
AM-1200 EP	Jet Fuel Compositions and Methods for Making and Using the Same	Neil Renninger Jason Ryder Karl Fisher	EP 07874140.2		EP 2099884	09/16/09		
AM-1200 IN	Jet Fuel Compositions and Methods for Making and Using the Same	Neil Renninger Jason Ryder Karl Fisher	IN 3533/CHENP/2009					
AM-1200 ZA	Jet Fuel Compositions and Methods for Making and Using the Same	Neil Renninger Jason Ryder Karl Fisher	ZA 2009/03366		ZA 2009/03366	10/27/10		
AM-1300 PCT	Dial-A-Pump	Ena Cratsenburg Rahul Shendure	PCT/US2008/012107	10/24/08	WO 2009/055024	04/30/09		
AM-1300 BR	Dial-A-Pump	Ena Cratsenburg Rahul Shendure	BR PI0819117-4					
AM-1300 EP	Dial-A-Pump	Ena Cratsenburg Rahul Shendure	EP 08842895.8		EP 2209737	07/28/10		

As of: September 27, 2013

*Indicates Total Collateral.

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
AM-1400	Production of Isoprenoids	Hiroko Tsuruta Jacob R. Lenihan Rika Regentin	US 12/234,589	09/19/08	US 2009/0137014	05/28/09		
AM-1400 PCT	Production of Isoprenoids	Hiroko Tsuruta Jacob R. Lenihan Rika Regentin	PCT/US2008/010886	09/19/08	WO 2009/042070	04/02/09		
AM-1400 AU	Production of Isoprenoids	Hiroko Tsuruta Jacob R. Lenihan Rika Regentin	AU 2008305655					
AM-1400 BR	Production of Isoprenoids	Hiroko Tsuruta Jacob R. Lenihan Rika Regentin	BR PI0816951-9					
AM-1400 CA	Production of Isoprenoids	Hiroko Tsuruta Jacob R. Lenihan Rika Regentin	CA 2,700,211					
AM-1400 CN	Production of Isoprenoids	Hiroko Tsuruta Jacob R. Lenihan Rika Regentin	CN 200880117160.7		CN 101868532A	10/20/10		
AM-1400 EP	Production of Isoprenoids	Hiroko Tsuruta Jacob R. Lenihan Rika Regentin	EP 08832899.2		EP 2217711	08/18/10		
AM-1400 IN	Production of Isoprenoids	Hiroko Tsuruta Jacob R. Lenihan Rika Regentin	IN 2183/CHENP/2010		IN 2183/CHENP/2010A	12/02/11		
AM-1400 JP	Production of Isoprenoids	Hiroko Tsuruta Jacob R. Lenihan Rika Regentin	JP 2010-525833					
AM-1400 MX	Production of Isoprenoids	Hiroko Tsuruta Jacob R. Lenihan Rika Regentin	MX/a/2010/002990				MX 302107	08/08/12
AM-1400 ZA	Production of Isoprenoids	Hiroko Tsuruta Jacob R. Lenihan Rika Regentin	ZA 2010/02000				ZA 2010/02000	05/25/11
AM-1700	Methods of Monitoring Metabolic Pathways	Sunil Bajad Michael Leavell	US 12/361,478	01/28/09	US 2009/0203019	08/13/09	US 8,450,080	05/28/13

As of: September 27, 2013

*Indicates Total Collateral.

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
AM-1700 D1	Methods of Monitoring Metabolic Pathways	Sunil Bajad Michael Leavell	US 13/870,911	04/25/13				
AM-1700 PCT	Methods of Monitoring Metabolic Pathways	Sunil Bajad Michael Leavell	PCT/US2009/032249	01/28/09	WO 2009/097339	08/06/09		
AM-1700 BR	Methods of Monitoring Metabolic Pathways	Sunil Bajad Michael Leavell	BR PI0906620-9					
AM-1700 EP	Methods of Monitoring Metabolic Pathways	Sunil Bajad Michael Leavell	EP 09705227.8		EP 2247746	08/06/09		
AM-1800 PCT	Expression of Heterologous Sequences	Zachary Serber Arle Kruckeberg	PCT/US2009/039769	04/07/09	WO 2009/126623	10/15/09		
AM-1800 AU	Expression of Heterologous Sequences	Zachary Serber Arle Kruckeberg	AU 2009233906					
AM-1800 BR	Expression of Heterologous Sequences	Zachary Serber Arle Kruckeberg	BR PI0911038					
AM-1800 EP	Expression of Heterologous Sequences	Zachary Serber Arle Kruckeberg	EP 09729776.6		EP 2262892	12/22/10		
AM-1800 JP	Expression of Heterologous Sequences	Zachary Serber Arle Kruckeberg	JP 2011-504126		JP 2011-517410	06/09/11		
AM-1800 MX	Expression of Heterologous Sequences	Zachary Serber Arle Kruckeberg	MX/a/2010/011068		MX/a/10/011068	12/14/12		
AM-1800 ZA	Expression of Heterologous Sequences	Zachary Serber Arle Kruckeberg	ZA 2010/06736				ZA 2010/06736	03/28/13
AM-1900	Jet Fuel Compositions and Methods of Making and Using the Same	Jason Ryder	US 12/431,769	04/29/09	US 2009/0272352	11/05/09	US 7,671,245	03/02/10
AM-1900 PCT	Fuel Compositions Comprising an Amorphane or a Stereoisomer Thereof and Methods of Making and Using Same	Jason Ryder	PCT/US2009/042189	04/29/09	WO 2009/134946	11/05/09		

As of: September 27, 2013

*Indicates Total Collateral.

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
AM-1900 AU	Fuel Compositions Comprising an Amorphane or a Stereoisomer Thereof and Methods of Making and Using Same	Jason Ryder	AU 2009243064					
AM-1900 BR	Fuel Compositions Comprising an Amorphane or a Stereoisomer Thereof and Methods of Making and Using Same	Jason Ryder	BR PI0911865-9					
AM-1900 CA	Fuel Compositions Comprising an Amorphane or a Stereoisomer Thereof and Methods of Making and Using Same	Jason Ryder	CA 2,723,163					
AM-1900 CN	Fuel Compositions Comprising an Amorphane or a Stereoisomer Thereof and Methods of Making and Using Same	Jason Ryder	CN 200980124831.7		CN102076831A	05/25/11		
AM-1900 EP	Fuel Compositions Comprising an Amorphane or a Stereoisomer Thereof and Methods of Making and Using Same	Jason Ryder	EP 09739748.3		EP 2288675	03/02/11	EP 2288675	06/12/13
AM-1900 EP-DE	Fuel Compositions Comprising an Amorphane or a Stereoisomer Thereof and Methods of Making and Using Same	Jason Ryder	EP 09739748.3		EP 2288675	03/02/11	EP 2288675	06/12/13

As of: September 27, 2013

*Indicates Total Collateral.

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
AM-1900 EP-FR	Fuel Compositions Comprising an Amorphane or a Stereoisomer Thereof and Methods of Making and Using Same	Jason Ryder	EP 09739748.3		EP 2288675	03/02/11	EP 2288675	06/12/13
AM-1900 EP-GB	Fuel Compositions Comprising an Amorphane or a Stereoisomer Thereof and Methods of Making and Using Same	Jason Ryder	EP 09739748.3		EP 2288675	03/02/11	EP 2288675	06/12/13
AM-1900 IN	Fuel Compositions Comprising an Amorphane or a Stereoisomer Thereof and Methods of Making and Using Same	Jason Ryder	IN 7530/CHEN/2010		IN 7530/CHENP/2010	08/05/11		
AM-1900 ZA	Fuel Compositions Comprising an Amorphane or a Stereoisomer Thereof and Methods of Making and Using Same	Jason Ryder	ZA 2010/07910				ZA 2010/07910	02/29/12
AM-1901	Jet Fuel Compositions and Methods of Making and Using the Same	Jason Ryder	US 12/432,733	04/29/09	US 2009/0272119	11/05/09	US 8,106,247	01/31/12
AM-2100	Farnesene Interpolymers	Derek James McPhee	US 12/552,282	09/01/09	US 2010/0056714	03/04/10	US 8,217,128	07/10/12
AM-2100 PCT	Farnesene Interpolymers	Derek James McPhee	PCT/US2009/004959	09/03/09	WO 2010/027464	03/11/10		
AM-2100 AU	Farnesene Interpolymers	Derek James McPhee	AU 2009288676					
AM-2100 BR	Farnesene Interpolymers	Derek James McPhee	BR PI0918225-0					
AM-2100 CA	Farnesene Interpolymers	Derek James McPhee	CA 2,735,257					
AM-2100 CN	Farnesene Interpolymers	Derek James McPhee	CN 200980138182.6		CN102164974A	08/24/11	CN ZL200980138182.6	11/21/12
AM-2100 EP	Farnesene Interpolymers	Derek James McPhee	EP 09789249.1		EP 2328943	06/08/11	EP 2328943	01/25/12
AM-2100 EP-CH	Farnesene Interpolymers	Derek James McPhee	EP 09789249.1		EP 2328943	06/08/11	EP 2328943	01/25/12

As of: September 27, 2013

*Indicates Total Collateral.

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
AM-2100 EP-DE	Farnesene Interpolymers	Derek James McPhee	EP 09789249.1		EP 2328943	06/08/11	EP 2328943	01/25/12
AM-2100 EP-ES	Farnesene Interpolymers	Derek James McPhee	EP 09789249.1		EP 2328943	06/08/11	EP 2328943	01/25/12
AM-2100 EP-FR	Farnesene Interpolymers	Derek James McPhee	EP 09789249.1		EP 2328943	06/08/11	EP 2328943	01/25/12
AM-2100 EP-GB	Farnesene Interpolymers	Derek James McPhee	EP 09789249.1		EP 2328943	06/08/11	EP 2328943	01/25/12
AM-2100 EP-IE	Farnesene Interpolymers	Derek James McPhee	EP 09789249.1		EP 2328943	06/08/11	EP 2328943	01/25/12
AM-2100 EP-IT	Farnesene Interpolymers	Derek James McPhee	EP 09789249.1		EP 2328943	06/08/11	EP 2328943	01/25/12
AM-2100 EP-NL	Farnesene Interpolymers	Derek James McPhee	EP 09789249.1		EP 2328943	06/08/11	EP 2328943	01/25/12
AM-2100 EP-SE	Farnesene Interpolymers	Derek James McPhee	EP 09789249.1		EP 2328943	06/08/11	EP 2328943	01/25/12
AM-2100 IN	Farnesene Interpolymers	Derek James McPhee	IN 2210/CHENP/2011					
AM-2100 JP	Farnesene Interpolymers	Derek James McPhee	JP 2011-526040		JP 2012-502136A	01/26/12		
AM-2100 KR	Farnesene Interpolymers	Derek James McPhee	KR 10-2011-7007803	04/04/11	KR 10-2011-0065502	06/15/11		
AM-2100 MX	Farnesene Interpolymers	Derek James McPhee	MX/a/2011/002438	04/04/11			MX 294796	01/16/12
AM-2100 SG	Farnesene Interpolymers	Derek James McPhee	SG 201101526-0	03/03/11				
AM-2100 TW	Farnesene Interpolymers	Derek James McPhee	TW 098129823	09/04/09				
AM-2100 ZA	Farnesene Interpolymers	Derek James McPhee	ZA 2011/01512				ZA 2011/01512	04/25/12
AM-2101	Polyfarnesenes by Metal-Catalyzed Insertion Polymerizations	Derek James McPhee	US 13/365,250	02/02/12	US 2012/0130033	05/24/12	US 8,334,353	12/18/12
AM-2102	Farnesene Interpolymers	Derek James McPhee	US 13/480,490	05/25/12	US 2012/0244304	09/27/12		
AM-2110	Polyfarnesenes	Derek James McPhee Adam Safir Joseph G. Doolan Craig L. Reeder	US 13/409,129	03/01/12	US 2012/0165474	06/28/12		
AM-2200	Jet Fuel Compositions	Jason Ryder	US 12/393,024	02/25/08			US 7,589,243	09/15/09
AM-2200 PCT	Jet Fuel Compositions	Jason Ryder	PCT/US2009/005158	09/16/09	WO 2010/033183	03/25/10		
AM-2200 AU	Jet Fuel Compositions	Jason Ryder	AU 2009292619					
AM-2200 BR	Jet Fuel Compositions	Jason Ryder	BR PI0918638-7					
AM-2200 CA	Jet Fuel Compositions	Jason Ryder	CA 2,736,759					
AM-2200 CN	Jet Fuel Compositions	Jason Ryder	CN 200980144962.1		CN 102209768A	10/05/11	CN ZL200980144962.1	09/04/13
AM-2200 EP	Jet Fuel Compositions	Jason Ryder	EP 09789314.3	04/13/11	EP 2342310	07/13/11	EP 2342310	01/09/13
AM-2200 EP-DE	Jet Fuel Compositions	Jason Ryder	EP 09789314.3	04/13/11	EP 2342310	07/13/11	EP 2342310	01/09/13
AM-2200 EP-ES	Jet Fuel Compositions	Jason Ryder	EP 09789314.3	04/13/11	EP 2342310	07/13/11	EP 2342310	01/09/13
AM-2200 EP-FR	Jet Fuel Compositions	Jason Ryder	EP 09789314.3	04/13/11	EP 2342310	07/13/11	EP 2342310	01/09/13
AM-2200 EP-GB	Jet Fuel Compositions	Jason Ryder	EP 09789314.3	04/13/11	EP 2342310	07/13/11	EP 2342310	01/09/13

As of: September 27, 2013

*Indicates Total Collateral.

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
AM-2200 EP-IT	Jet Fuel Compositions	Jason Ryder	EP 09789314.3	04/13/11	EP 2342310	07/13/11	EP 2342310	01/09/13
AM-2200 IN	Jet Fuel Compositions	Jason Ryder	IN 1816/CHENP/2011	03/15/11	IN 1816/CHENP/2011A	12/02/11		
AM-2200 JP	Jet Fuel Compositions	Jason Ryder	JP 2011-527811					
AM-2200 KR	Jet Fuel Compositions	Jason Ryder	KR 10-2011-7008675	04/15/11	KR 10-2011- 0056416	05/27/11		
AM-2200 MX	Jet Fuel Compositions	Jason Ryder	MX/a/2011/002831					
AM-2200 SG	Jet Fuel Compositions	Jason Ryder	SG 201101827-2					
AM-2200 ZA	Jet Fuel Compositions	Jason Ryder	ZA 2011/01853	03/10/11			ZA 2011/01853	05/30/12
AM-2300	Farnesene Dimers and/or Farnesane Dimers and Compositions Thereof	Frank X. Woolard Karl Fisher	US 12/409,437	03/23/09			US 7,592,295	09/22/09
AM-2310	Lubricant Compositions	Frank X. Woolard Karl Fisher	US 12/577,093	10/09/09			US 7,691,792	04/06/10
AM-2310 PCT	Farnesene Dimers and/or Farnesane Dimers and Compositions Thereof	Frank X. Woolard Karl Fisher	PCT/US2009/005543	10/09/09	WO 2010/042208	04/15/10		
AM-2310 BR	Farnesene Dimers and/or Farnesane Dimers and Compositions Thereof	Frank X. Woolard Karl Fisher	BR PI0919697-8					
AM-2310 EP	Farnesene Dimers and/or Farnesane Dimers and Compositions Thereof	Frank X. Woolard Karl Fisher	EP 09740208.5		EP 2349956	08/03/11		
AM-2310 US	Farnesene Dimers and/or Farnesane Dimers and Compositions Thereof	Frank X. Woolard Karl Fisher	US 13/123,514	04/08/11 371(C): 08/02/11	US 2011/0282113	11/17/11		
AM-2400	Compositions and Methods for the Rapid Assembly of Polynucleotides	Zach Serber Raymond Lowe Jeffrey A. Ubersax Sunil S. Chandran	US 12/622,401	11/19/09	US 2010/0136633	06/03/10	US 8,221,982	07/17/12
AM-2400 C1	Compositions and Methods for the Rapid Assembly of Polynucleotides	Zach Serber Raymond Lowe Jeffrey A. Ubersax Sunil S. Chandran	US 12/684,874	01/08/10	US 2010/0124768	05/10/10	US 8,110,360	02/07/12

As of: September 27, 2013

*Indicates Total Collateral.

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
AM-2400 C2	Compositions and Methods for the Rapid Assembly of Polynucleotides	Zach Serber Raymond Lowe Jeffrey A. Ubersax Sunil S. Chandran	US 13/430,322	03/26/12	US 2012/0245056	09/27/12		
AM-2400 PCT	Compositions and Methods for the Rapid Assembly of Polynucleotides	Zach Serber Raymond Lowe Jeffrey A. Ubersax Sunil S. Chandran Erik Jedediah Dean Darren M. Platt Kenneth Toshiki Takeoka	PCT/US2009/065048	11/19/09	WO 2010/059763	05/27/10		
AM-2400 AU	Compositions and Methods for the Rapid Assembly of Polynucleotides	Zach Serber Raymond Lowe Jeffrey A. Ubersax Sunil S. Chandran Erik Jedediah Dean Darren M. Platt Kenneth Toshiki Takeoka	AU 2009316660					
AM-2400 BR	Compositions and Methods for the Rapid Assembly of Polynucleotides	Zach Serber Raymond Lowe Jeffrey A. Ubersax Sunil S. Chandran Erik Jedediah Dean Darren M. Platt Kenneth Toshiki Takeoka	BR PI0922187-5					
AM-2400 CA	Compositions and Methods for the Rapid Assembly of Polynucleotides	Zach Serber Raymond Lowe Jeffrey A. Ubersax Sunil S. Chandran Erik Jedediah Dean Darren M. Platt Kenneth Toshiki Takeoka	CA 2,744,153					

As of: September 27, 2013

*Indicates Total Collateral.

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
AM-2400 CN	Compositions and Methods for the Rapid Assembly of Polynucleotides	Zach Serber Raymond Lowe Jeffrey A. Ubersax Sunil S. Chandran Erik Jedediah Dean Darren M. Platt Kenneth Toshiki Takeoka	CN 200980154897.0					
AM-2400 EP	Compositions and Methods for the Rapid Assembly of Polynucleotides	Zach Serber Raymond Lowe Jeffrey A. Ubersax Sunil S. Chandran Erik Jedediah Dean Darren M. Platt Kenneth Toshiki Takeoka	EP 09764127.8-2403		EP 2358875	08/24/11		
AM-2400 HK	Compositions and Methods for the Rapid Assembly of Polynucleotides	Zach Serber Raymond Lowe Jeffrey A. Ubersax Sunil S. Chandran Erik Jedediah Dean Darren M. Platt Kenneth Toshiki Takeoka	HK 12100835.5		HK 1160485	08/17/12		
AM-2400 IN	Compositions and Methods for the Rapid Assembly of Polynucleotides	Zach Serber Raymond Lowe Jeffrey A. Ubersax Sunil S. Chandran Erik Jedediah Dean Darren M. Platt Kenneth Toshiki Takeoka	IN 4129/CHENP/2011		IN 4129/CHENP/2011	09/07/12		

As of: September 27, 2013

*Indicates Total Collateral.

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
AM-2400 JP	Compositions and Methods for the Rapid Assembly of Polynucleotides	Zach Serber Raymond Lowe Jeffrey A. Ubersax Sunil S. Chandran Erik Jedediah Dean Darren M. Platt Kenneth Toshiki Takeoka	JP 2011-537596					
AM-2400 KR	Compositions and Methods for the Rapid Assembly of Polynucleotides	Zach Serber Raymond Lowe Jeffrey A. Ubersax Sunil S. Chandran Erik Jedediah Dean Darren M. Platt Kenneth Toshiki Takeoka	KR 10-2011-7014144		KR 10-2011-0102351	09/16/11		
AM-2400 MX	Compositions and Methods for the Rapid Assembly of Polynucleotides	Zach Serber Raymond Lowe Jeffrey A. Ubersax Sunil S. Chandran Erik Jedediah Dean Darren M. Platt Kenneth Toshiki Takeoka	MX/a/2011/005195					
AM-2400 MX D1	Compositions and Methods for the Assembly of Polynucleotides	Zach Serber Raymond Lowe Jeffrey A. Ubersax Sunil S. Chandran Erik Jedediah Dean Darren M. Platt Kenneth Toshiki Takeoka	MX/a/2012/011877					

As of: September 27, 2013

*Indicates Total Collateral.

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
AM-2400 SG	Compositions and Methods for the Rapid Assembly of Polynucleotides	Zach Serber Raymond Lowe Jeffrey A. Ubersax Sunil S. Chandran Erik Jedediah Dean Darren M. Platt Kenneth Toshiki Takeoka	SG 201103627-4				SG 171760	09/14/12
AM-2400 ZA	Compositions and Methods for the Rapid Assembly of Polynucleotides	Zach Serber Raymond Lowe Jeffrey A. Ubersax Sunil S. Chandran Erik Jedediah Dean Darren M. Platt Kenneth Toshiki Takeoka	ZA 2011/03637				ZA 2011/03637	08/29/13
AM-2500	Microbial Derived Isoprene and Methods for Making the Same	Derek James McPhee	US 12/659,216	03/01/10	US 2010/0261942	10/14/10	US 8,324,442	12/04/12
AM-2500 D1	Microbial Derived Isoprene and Methods for Making the Same	Derek James McPhee	US 13/629,623	09/28/12	US 2013/0030227	01/31/13	US 8,492,605	07/23/13
AM-2500 D2	Microbial Derived Isoprene and Methods for Making the Same	Derek James McPhee	US 13/887,381	05/06/13	US 2013/0221280	08/29/13		
AM-2500 PCT	Microbial Derived Isoprene and Methods for Making the Same	Derek James McPhee	PCT/US2010/025826	03/02/10	WO 2010/101855	09/10/10		
AM-2500 BR	Microbial Derived Isoprene and Methods for Making the Same	Derek James McPhee	BR PI1013216-3					
AM-2500 EP	Microbial Derived Isoprene and Methods for Making the Same	Derek James McPhee	EP 10708846		EP 2403816	01/11/12		

As of: September 27, 2013

*Indicates Total Collateral.

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
AM-2600	Stabilization & Hydrogenation Methods for Microbial-Derived Olefins	Nicholas L. Ohler Roberto Vazquez	US 12/753,413	04/02/10	US 2010/0267971	10/21/10	US 8,519,204	08/27/13
AM-2600 D1	Stabilization & Hydrogenation Methods for Microbial-Derived Olefins	Nicholas L. Ohler Roberto Vazquez	US 13/951,137	07/25/13				
AM-2600 D2	Stabilization & Hydrogenation Methods for Microbial-Derived Olefins	Nicholas L. Ohler Roberto Vazquez	US 13/951,160	07/25/13				
AM-2600 PCT	Stabilization & Hydrogenation Methods for Microbial-Derived Olefins	Nicholas L. Ohler Roberto Vazquez	PCT/US2010/029774	04/02/10	WO 2010/115097	10/07/10		
AM-2600 AU	Stabilization & Hydrogenation Methods for Microbial-Derived Olefins	Nicholas L. Ohler Roberto Vazquez	AU 2010232469					
AM-2600 BR	Stabilization & Hydrogenation Methods for Microbial-Derived Olefins	Nicholas L. Ohler Roberto Vazquez	BR PI1015250-4					
AM-2600 CA	Stabilization & Hydrogenation Methods for Microbial-Derived Olefins	Nicholas L. Ohler Roberto Vazquez	CA 2,757,000					
AM-2600 CN	Stabilization & Hydrogenation Methods for Microbial-Derived Olefins	Nicholas L. Ohler Roberto Vazquez	CN 201080024164.8		CN 102448916	05/09/12		
AM-2600 EP	Stabilization & Hydrogenation Methods for Microbial-Derived Olefins	Nicholas L. Ohler Roberto Vazquez	EP 10712281.4		EP 2414311	02/08/12		

As of: September 27, 2013

*Indicates Total Collateral.

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
AM-2600 MX	Stabilization & Hydrogenation Methods for Microbial-Derived Olefins	Nicholas L. Ohler Roberto Vazquez	MX/a/2011/010140					
AM-2600 TT	Stabilization & Hydrogenation Methods for Microbial-Derived Olefins	Nicholas L. Ohler Roberto Vazquez	TT/A/2011/00175					
AM-3000	Method for Generating a Genetically Modified Microbe	Jeffrey A. Ubersax	US 12/791,717	06/01/10	US 2010/0304490	12/02/10	US 8,357,527	01/22/13
AM-3000 C1	Method for Generating a Genetically Modified Microbe	Jeffrey A. Ubersax	US 13/707,593	12/06/12	US 2013/0089914	04/11/13		
AM-3000 PCT	Method for Generating a Genetically Modified Microbe	Jeffrey A. Ubersax	PCT/US2010/036861	06/01/10	WO 2010/141438	12/09/10		
AM-3000 AU	Method for Generating a Genetically Modified Microbe	Jeffrey A. Ubersax	AU 2010256803					
AM-3000 BR	Method for Generating a Genetically Modified Microbe	Jeffrey A. Ubersax	BR PI1013889-7					
AM-3000 CA	Method for Generating a Genetically Modified Microbe	Jeffrey A. Ubersax	CA 2,762,822					
AM-3000 CN	Method for Generating a Genetically Modified Microbe	Jeffrey A. Ubersax	CN 201080024339.5					
AM-3000 EP	Method for Generating a Genetically Modified Microbe	Jeffrey A. Ubersax	EP 10721095.7		EP 2438156	04/11/12		
AM-3000 HK	Method for Generating a Genetically Modified Microbe	Jeffrey A. Ubersax	HK 12105716.8	06/12/12				

As of: September 27, 2013

*Indicates Total Collateral.

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
AM-3000 IN	Method for Generating a Genetically Modified Microbe	Jeffrey A. Ubersax	IN 9940/CHENP/2011		IN 9940/CHENP/2011A	04/12/13		
AM-3000 JP	Method for Generating a Genetically Modified Microbe	Jeffrey A. Ubersax	JP 2012-513352		JP 2012-528570	11/15/12		
AM-3000 KR	Method for Generating a Genetically Modified Microbe	Jeffrey A. Ubersax	KR 10-2011-7029735		KR 10-2012-0034652	04/12/12		
AM-3000 MX	Method for Generating a Genetically Modified Microbe	Jeffrey A. Ubersax	MX/a/2011/012765					
AM-3000 MX D1	Method for Generating a Genetically Modified Microbe	Jeffrey A. Ubersax	MX/a/2013/009952	08/29/13				
AM-3000 SG	Method for Generating a Genetically Modified Microbe	Jeffrey A. Ubersax	SG 201108898-6					
AM-3000 ZA	Method for Generating a Genetically Modified Microbe	Jeffrey A. Ubersax	ZA 2011/08380				ZA 2011/08380	01/30/13
AM-3100 PCT	Genetically Modified Microbe	Jeffrey A. Ubersax Darren M. Platt	PCT/US2010/036879	06/01/10	WO 2010/141452	12/09/10		
AM-3100 BR	Genetically Modified Microbe	Jeffrey A. Ubersax Darren M. Platt	BR PI1013896-0					
AM-3100 EP	Genetically Modified Microbe	Jeffrey A. Ubersax Darren M. Platt	EP 10721260.7		EP 2438157	04/11/12		
AM-3200	Polyfarnesenes	Derek James McPhee	US 12/552,278	09/01/09	US 2010/0056743	03/04/10	US 8,048,976	11/01/11
AM-3201	Polyfarnesenes	Derek James McPhee	US 13/235,530	09/19/11	US 2012/0010370	01/12/12	US 8,314,196	11/20/12
AM-3300	Adhesive Compositions Comprising Polyfarnesene	Derek James McPhee Matthew J. Graham	US 12/507,801	07/23/09			US 7,655,739	02/02/10
AM-3300 PCT	Adhesive Compositions Comprising Polyfarnesene	Derek James McPhee Matthew J. Graham	PCT/US2009/004958	09/03/09	WO 2010/027463	03/11/10		
AM-3300 AU	Adhesive Compositions Comprising Polyfarnesene	Derek James McPhee Matthew J. Graham	AU 2009288675	03/04/11				

As of: September 27, 2013

*Indicates Total Collateral.

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
AM-3300 BR	Adhesive Compositions Comprising Polyfarnesene	Derek James McPhee Matthew J. Graham	BR PI0918181-4					
AM-3300 CA	Adhesive Compositions Comprising Polyfarnesene	Derek James McPhee Matthew J. Graham	CA 2,735,255					
AM-3300 CN	Adhesive Compositions Comprising Polyfarnesene	Derek James McPhee Matthew J. Graham	CN 200980143983.1		CN 102203145A	09/28/11		
AM-3300 EP	Adhesive Compositions Comprising Polyfarnesene	Derek James McPhee Matthew J. Graham	EP 09789248.3	03/14/11	EP 2334707	06/22/11	EP 2334707	02/01/12
AM-3300 EP-CH	Adhesive Compositions Comprising Polyfarnesene	Derek James McPhee Matthew J. Graham	EP 09789248.3	03/14/11	EP 2334707	06/22/11	EP 2334707	02/01/12
AM-3300 EP-DE	Adhesive Compositions Comprising Polyfarnesene	Derek James McPhee Matthew J. Graham	EP 09789248.3	03/14/11	EP 2334707	06/22/11	EP 2334707	02/01/12
AM-3300 EP-ES	Adhesive Compositions Comprising Polyfarnesene	Derek James McPhee Matthew J. Graham	EP 09789248.3	03/14/11	EP 2334707	06/22/11	EP 2334707	02/01/12
AM-3300 EP-FR	Adhesive Compositions Comprising Polyfarnesene	Derek James McPhee Matthew J. Graham	EP 09789248.3	03/14/11	EP 2334707	06/22/11	EP 2334707	02/01/12
AM-3300 EP-GB	Adhesive Compositions Comprising Polyfarnesene	Derek James McPhee Matthew J. Graham	EP 09789248.3	03/14/11	EP 2334707	06/22/11	EP 2334707	02/01/12
AM-3300 EP-IE	Adhesive Compositions Comprising Polyfarnesene	Derek James McPhee Matthew J. Graham	EP 09789248.3	03/14/11	EP 2334707	06/22/11	EP 2334707	02/01/12
AM-3300 EP-IT	Adhesive Compositions Comprising Polyfarnesene	Derek James McPhee Matthew J. Graham	EP 09789248.3	03/14/11	EP 2334707	06/22/11	EP 2334707	02/01/12
AM-3300 EP-NL	Adhesive Compositions Comprising Polyfarnesene	Derek James McPhee Matthew J. Graham	EP 09789248.3	03/14/11	EP 2334707	06/22/11	EP 2334707	02/01/12
AM-3300 EP-SE	Adhesive Compositions Comprising Polyfarnesene	Derek James McPhee Matthew J. Graham	EP 09789248.3	03/14/11	EP 2334707	06/22/11	EP 2334707	02/01/12
AM-3300 HK	Adhesive Compositions Comprising Polyfarnesene	Derek James McPhee Matthew J. Graham	HK 11106732.7				HK 1152711B	08/31/12
AM-3300 IN	Adhesive Compositions Comprising Polyfarnesene	Derek James McPhee Matthew J. Graham	IN 2177/CHENP/2011					
AM-3300 JP	Adhesive Compositions Comprising Polyfarnesene	Derek James McPhee Matthew J. Graham	JP 2011-526039		JP 2012-502135A	01/26/12		
AM-3300 KR	Adhesive Compositions Comprising Polyfarnesene	Derek James McPhee Matthew J. Graham	KR 10-2011-7007820	04/04/11	KR 10-2011-0065505	06/15/11		

As of: September 27, 2013

*Indicates Total Collateral.

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
AM-3300 MX	Adhesive Compositions Comprising Polyfarnesene	Derek James McPhee Matthew J. Graham	MX/a/2011/002390	03/03/11			MX 294795	01/16/12
AM-3300 SG	Adhesive Compositions Comprising Polyfarnesene	Derek James McPhee Matthew J. Graham	SG 201101523-7	03/03/11			SG 169211	10/15/12
AM-3300 ZA	Adhesive Compositions Comprising Polyfarnesene	Derek James McPhee Matthew J. Graham	ZA 2011/01514				ZA 2011/01514	04/25/12
AM-3301	Compositions Comprising Polyfarnesene	Derek James McPhee	US 12/694,120	01/26/10			US 7,759,444	07/20/10
AM-3302	Compositions Comprising Polyfarnesene	Derek James McPhee	US 12/825,357	06/29/10	US 2010/0331800	12/30/10	US 7,868,114	01/11/11
AM-3303	Compositions Comprising Polyfarnesene	Derek James McPhee	US 12/825,364	06/29/10	US 2010/0331511	12/30/10	US 7,868,115	01/11/11
AM-3400	Nucleic Acids, Compositions and Methods for the Excision of Target Nucleic Acids	Kirsten R. Benjamin	US 12/978,061	12/23/10			US 7,919,605	04/05/11
AM-3410	Nucleic Acids, Compositions and Methods for the Excision of Target Nucleic Acids	Kirsten R. Benjamin	US 13/220,553	08/29/11	US 2012/0052582	03/01/12		
AM-3410 PCT	Nucleic Acids, Compositions and Methods for the Excision of Target Nucleic Acids	Kirsten R. Benjamin	PCT/US2011/049615	08/29/11	WO 2012/030747	03/08/12		
AM-3410 AU	Nucleic Acids, Compositions and Methods for the Excision of Target Nucleic Acids	Kirsten R. Benjamin	AU 2011296245	03/20/13				
AM-3410 BR	Nucleic Acids, Compositions and Methods for the Excision of Target Nucleic Acids	Kirsten R. Benjamin	PI1120130048107	02/28/13				
AM-3410 CA	Nucleic Acids, Compositions and Methods for the Excision of Target Nucleic Acids	Kirsten R. Benjamin	CA 2,809,645	02/26/13				

As of: September 27, 2013

*Indicates Total Collateral.

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
AM-3410 CN	Nucleic Acids, Compositions and Methods for the Excision of Target Nucleic Acids	Kirsten R. Benjamin	CN 201180051803.4	04/26/13				
AM-3410 EP	Nucleic Acids, Compositions and Methods for the Excision of Target Nucleic Acids	Kirsten R. Benjamin	EP 11755188.7	03/06/13	EP 2611923	07/10/13		
AM-3410 HK	Nucleic Acids, Compositions and Methods for the Excision of Target Nucleic Acids	Kirsten R. Benjamin	HK 13108147.0	07/11/13				
AM-3410 IN	Nucleic Acids, Compositions and Methods for the Excision of Target Nucleic Acids	Kirsten R. Benjamin	IN 1663/DELNP/2013	02/22/13				
AM-3410 JP	Nucleic Acids, Compositions and Methods for the Excision of Target Nucleic Acids	Kirsten R. Benjamin	JP 2013-526203	04/04/13				
AM-3410 KR	Nucleic Acids, Compositions and Methods for the Excision of Target Nucleic Acids	Kirsten R. Benjamin	KR 10-2013-7006317	03/12/13				
AM-3410 MX	Nucleic Acids, Compositions and Methods for the Excision of Target Nucleic Acids	Kirsten R. Benjamin	MX/a/2013/002249	02/26/13				
AM-3410 SG	Nucleic Acids, Compositions and Methods for the Excision of Target Nucleic Acids	Kirsten R. Benjamin	SG 201301254-7	02/20/13				
AM-3410 ZA	Nucleic Acids, Compositions and Methods for the Excision of Target Nucleic Acids	Kirsten R. Benjamin	ZA 2013/01177	02/14/13				

As of: September 27, 2013

*Indicates Total Collateral.

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
AM-3500	Squalane and Isosqualane Compositions and Methods For Preparing the Same	Karl Fisher Susan Jessica Schofer David B. Kanne	US 13/112,991	05/20/11	US 2011/0287988	11/24/11		
AM-3500 PCT	Squalane and Isosqualane Compositions and Methods For Preparing the Same	Karl Fisher Susan Jessica Schofer David B. Kanne	PCT/US2011/037341	05/20/11	WO 2011/146837	11/24/11		
AM-3500 BR	Squalane and Isosqualane Compositions and Methods For Preparing the Same	Karl Fisher Susan Jessica Schofer David B. Kanne	BR 112012028932-2	11/22/12				
AM-3500 EP	Squalane and Isosqualane Compositions and Methods For Preparing the Same	Karl Fisher Susan Jessica Schofer David B. Kanne	EP 11724846.8	12/20/12	EP 2574187	04/03/13		
AM-3500 JP	Squalane and Isosqualane Compositions and Methods For Preparing the Same	Karl Fisher Susan Jessica Schofer David B. Kanne	JP 2013-511388	11/19/12	JP 2013-530145	07/25/13		
AM-3800	Methods for Purifying Bio-Organic Compounds	Pinar Tabur Glenn Dorin	US 13/198,711	08/05/11	US 2012/0040396	02/16/12		
AM-3800 PCT	Methods for Purifying Bio-Organic Compounds From Fermentation Broth Containing Surfactants By Temperature-Induced Phase Inversion	Pinar Tabur Glenn Dorin	PCT/US2011/047616	08/12/11	WO 2012/024186	02/23/12		
AM-3800 AU	Methods for Purifying Bio-Organic Compounds From Fermentation Broth Containing Surfactants By Temperature-Induced Phase Inversion	Pinar Tabur Glenn Dorin	AU 2011292231	11/29/12				

As of: September 27, 2013

*Indicates Total Collateral.

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
AM-3800 BR	Methods for Purifying Bio-Organic Compounds From Fermentation Broth Containing Surfactants By Temperature-Induced Phase Inversion	Pinar Tabur Glenn Dorin	BR 1120120274627	10/25/12				
AM-3800 CA	Methods for Purifying Bio-Organic Compounds From Fermentation Broth Containing Surfactants By Temperature-Induced Phase Inversion	Pinar Tabur Glenn Dorin	CA 2,796,438					
AM-3800 CN	Methods for Purifying Bio-Organic Compounds From Fermentation Broth Containing Surfactants By Temperature-Induced Phase Inversion	Pinar Tabur Glenn Dorin	CN 201180037472.9	01/30/13	CN 103052612A	04/17/13		
AM-3800 EP	Methods for Purifying Bio-Organic Compounds From Fermentation Broth Containing Surfactants By Temperature-Induced Phase Inversion	Pinar Tabur Glenn Dorin	EP 11749297.5	10/11/12	EP 2606018	06/26/13		
AM-3800 IN	Methods for Purifying Bio-Organic Compounds From Fermentation Broth Containing Surfactants By Temperature-Induced Phase Inversion	Pinar Tabur Glenn Dorin	IN 8861/DELNP/2012	10/11/12				
AM-3800 JP	Methods for Purifying Bio-Organic Compounds From Fermentation Broth Containing Surfactants By Temperature-Induced Phase Inversion	Pinar Tabur Glenn Dorin	JP 2013-524893	01/16/13				

As of: September 27, 2013

*Indicates Total Collateral.

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
AM-3800 KR	Methods for Purifying Bio-Organic Compounds From Fermentation Broth Containing Surfactants By Temperature-Induced Phase Inversion	Pinar Tabur Glenn Dorin	KR 10-2012-7028294	10/29/12				
AM-3800 MX	Methods for Purifying Bio-Organic Compounds From Fermentation Broth Containing Surfactants By Temperature-Induced Phase Inversion	Pinar Tabur Glenn Dorin	MX/a/2012/012705	10/31/12	MX/a/2012/012705	12/13/12		
AM-3800 ZA	Methods for Purifying Bio-Organic Compounds From Fermentation Broth Containing Surfactants By Temperature-Induced Phase Inversion	Pinar Tabur Glenn Dorin	ZA 2012/07717	10/15/12				
AM-3900 PCT	Graft Copolymers of Polyfarnesenes with Condensation Polymers	Derek James McPhee	PCT/US2011/045856	07/29/11	WO 2012/018682	02/09/12		
AM-3900 AU	Graft Copolymers of Polyfarnesenes with Condensation Polymers	Derek James McPhee	AU 2011286019	10/30/12				
AM-3900 BR	Graft Copolymers of Polyfarnesenes with Condensation Polymers	Derek James McPhee	BR 1120120292153	11/14/12				
AM-3900 CA	Graft Copolymers of Polyfarnesenes with Condensation Polymers	Derek James McPhee	CA 2,798,299	12/20/12				
AM-3900 CN	Graft Copolymers of Polyfarnesenes with Condensation Polymers	Derek James McPhee	CN 201180035389.8	01/18/13	CN 103052664 A	04/17/13		
AM-3900 EP	Graft Copolymers of Polyfarnesenes with Condensation Polymers	Derek James McPhee	EP 11746707.6	11/29/12	EP 2601229	06/12/13		

As of: September 27, 2013

*Indicates Total Collateral.

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
AM-3900 IN	Graft Copolymers of Polyfarnesenes with Condensation Polymers	Derek James McPhee	IN 9549/DELNP/2012	11/05/12				
AM-3900 JP	Graft Copolymers of Polyfarnesenes with Condensation Polymers	Derek James McPhee	JP 2013-523222	10/29/12				
AM-3900 KR	Graft Copolymers of Polyfarnesenes with Condensation Polymers	Derek James McPhee	KR 10-2012-7031759	12/04/12				
AM-3900 US	Graft Copolymers of Polyfarnesenes with Condensation Polymers	Derek James McPhee	US 13/811,665	01/22/13	US 2013/0123379	05/16/13		
AM-4000	Methods of Developing Sesquiterpene Synthase Variants	Lishan Zhao Lan Xu Patrick Westfall Andrew Main	US 13/363,588	02/01/12	US 2012/0196315	08/02/12	US 8,236,512	08/07/12
AM-4000 PCT	Methods of Developing Sesquiterpene Synthase Variants	Lishan Zhao Lan Xu Patrick Westfall Andrew Main	PCT/US2012/023446	02/01/12	WO 2012/106405	08/09/12		
AM-4000 AU	Methods of Developing Sesquiterpene Synthase Variants	Lishan Zhao Lan Xu Patrick Westfall Andrew Main	AU 2012212292	07/26/13				
AM-4000 BR	Methods of Developing Sesquiterpene Synthase Variants	Lishan Zhao Lan Xu Patrick Westfall Andrew Main	BR 1120130195746	07/31/13				
AM-4000 CA	Methods of Developing Sesquiterpene Synthase Variants	Lishan Zhao Lan Xu Patrick Westfall Andrew Main	tba					
AM-4000 CN	Methods of Developing Sesquiterpene Synthase Variants	Lishan Zhao Lan Xu Patrick Westfall Andrew Main	tba					

As of: September 27, 2013

*Indicates Total Collateral.

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
AM-4000 EP	Methods of Developing Sesquiterpene Synthase Variants	Lishan Zhao Lan Xu Patrick Westfall Andrew Main	tba					
AM-4000 HK	Methods of Developing Sesquiterpene Synthase Variants	Lishan Zhao Lan Xu Patrick Westfall Andrew Main	tba					
AM-4000 IN	Methods of Developing Sesquiterpene Synthase Variants	Lishan Zhao Lan Xu Patrick Westfall Andrew Main	7012/CHENP/2013	08/30/13				
AM-4000 JP	Methods of Developing Sesquiterpene Synthase Variants	Lishan Zhao Lan Xu Patrick Westfall Andrew Main	tba					
AM-4000 KR	Methods of Developing Sesquiterpene Synthase Variants	Lishan Zhao Lan Xu Patrick Westfall Andrew Main	tba					
AM-4000 MX	Methods of Developing Sesquiterpene Synthase Variants	Lishan Zhao Lan Xu Patrick Westfall Andrew Main	MX/a/2013/008903					
AM-4000 SG	Methods of Developing Sesquiterpene Synthase Variants	Lishan Zhao Lan Xu Patrick Westfall Andrew Main	tba					
AM-4000 ZA	Methods of Developing Sesquiterpene Synthase Variants	Lishan Zhao Lan Xu Patrick Westfall Andrew Main	ZA 2013/05797					
AM-4100	Gel-Encapsulated Microcolony Screening	Jeremy Agresti	US 13/360,620	01/27/12	US 2012/0196770	08/02/12		

As of: September 27, 2013

*Indicates Total Collateral.

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
AM-4100 PCT	Gel-Encapsulated Microcolony Screening	Jeremy Agresti	PCT/US2012/023024	01/27/12	WO 2012/103516	08/02/12		
AM-4100 AU	Gel-Encapsulated Microcolony Screening	Jeremy Agresti	AU 2012211052	08/14/13				
AM-4100 BR	Gel-Encapsulated Microcolony Screening	Jeremy Agresti	PI1120130178841	07/12/13				
AM-4100 CA	Gel-Encapsulated Microcolony Screening	Jeremy Agresti	tba	07/10/13				
AM-4100 CN	Gel-Encapsulated Microcolony Screening	Jeremy Agresti	tba					
AM-4100 EP	Gel-Encapsulated Microcolony Screening	Jeremy Agresti	EP 12705186.0	07/12/13				
AM-4100 HK	Gel-Encapsulated Microcolony Screening	Jeremy Agresti	tba					
AM-4100 IN	Gel-Encapsulated Microcolony Screening	Jeremy Agresti	IN 6148/DELNP/2013	07/09/13				
AM-4100 JP	Gel-Encapsulated Microcolony Screening	Jeremy Agresti	tba					
AM-4100 KR	Gel-Encapsulated Microcolony Screening	Jeremy Agresti	KR 10-2013-7022572	08/27/13				
AM-4100 MX	Gel-Encapsulated Microcolony Screening	Jeremy Agresti	MX/a/2013/008062	07/10/13				
AM-4100 SG	Gel-Encapsulated Microcolony Screening	Jeremy Agresti	SG 201305623-9	07/23/13				
AM-4100 ZA	Gel-Encapsulated Microcolony Screening	Jeremy Agresti	ZA 2013/04895	07/01/13				
AM-4200 PCT	Surfactants	Frank X. Woolard Derek J. McPhee	PCT/US2012/022451	01/24/12	WO 2012/103156	08/02/12		
AM-4300 PCT	Microbial Isoprenoid Production Using a Heterologous DXP Pathway	Lishan Zhao Kevin L. Dietzel Gale A. Wichmann	PCT/US2012/031395	03/30/12	WO 2012/135591	10/04/12		
AM-4400 PCT	Olefins and Methods for Making the Same	Nicholas L. Ohler Karl Fisher Jin Ki Hong	PCT/US2012/024922	02/13/12	WO 2012/141783	10/18/12		

As of: September 27, 2013

*Indicates Total Collateral.

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
AM-4600	Production of Acetyl-Coenzyme A Derived Compounds	Adam Meadows	US 13/467,783	05/09/12	US 2012/0288891	11/15/12		
AM-4600 PCT	Production of Acetyl-Coenzyme A Derived Compounds	Adam Meadows	PCT/US2012/037127	05/09/12	WO 2012/154854	11/15/12		
AM-4800	Methods for Genomic Modification of Yeast	Zach Serber Andrew Horwitz	US 13/459,034	04/27/12	US 2012/0277120	11/01/12		
AM-4800 PCT	Methods for Genomic Modification of Yeast	Zach Serber Andrew Horwitz	PCT/US2012/035657	04/27/12	WO 2012/149470	11/01/12		
AM-4900 PCT	Methods and Compositions for Detecting Microbial Production of Water-Immiscible Compounds	Jeffrey A. Ubersax Lucas Frenz	PCT/US2012/037351	05/10/12	WO 2012/158466			
AM-5000 PCT	Plasticizers	Frank X. Woolard Daniel Batzel	PCT/US2012/028956	03/13/12	WO 2012/158250	11/22/12		
AM-5200 PCT	Base Oils and Methods for Making the Same	Karl Fisher Nicholas Ohler Shakeel Tirmizi	PCT/US2012/024926	02/13/12	WO 2012/141784	10/18/12		
AM-5300 PCT	Derivatives of Hydrocarbon Terpenes	Frank X. Woolard Derek McPhee	PCT/US2012/048203	07/25/12	WO 2013/028307	02/28/13		
AM-5400	Production of Acetyl-Coenzyme A Derived Isoprenoids	Timothy Stevens Gardner Kristy Hawkins Adam Meadows Yoseph Tsegaye Annie Tsong	US 13/673,819	11/09/12			US 8,415,136	04/09/13

As of: September 27, 2013

*Indicates Total Collateral.

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
AM-5400 C1	Production of Acetyl-Coenzyme A Derived Isoprenoids	Timothy Stevens Gardner Kristy Hawkins Adam Meadows Yoseph Tsegaye Annie Tsong	US 13/752,293	01/28/13				
AM-5400 PCT	Production of Acetyl-Coenzyme A Derived Isoprenoids	Timothy Stevens Gardner Kristy Hawkins Adam Meadows Yoseph Tsegaye Annie Tsong	PCT/US2012/064532	11/09/12	WO 2013/071172	05/16/13		
AM-5500	Systems and Methods For Engineering Nucleic Acid Constructs Using Scoring Techniques	Darren M. Platt Michael W. Bissell Sunil S. Chandran Brian L. Hawthorne Jedediah Erik Dean Christopher Dolan	US 13/442,625	04/09/12			US 8,332,160	12/11/12
AM-5500 C1	Systems and Methods For Engineering Nucleic Acid Constructs Using Scoring Techniques	Darren M. Platt Michael W. Bissell Sunil S. Chandran Brian L. Hawthorne Jedediah Erik Dean Christopher Dolan	US 13/650,049	10/11/12	US 2013/0236942	09/12/13		
AM-5500 PCT	Systems and Methods For Engineering Nucleic Acid Constructs Using Scoring Techniques	Darren M. Platt Michael W. Bissell Sunil S. Chandran Brian L. Hawthorne Jedediah Erik Dean Christopher Dolan	PCT/US2012/065708	11/16/12	WO 2013/075049	05/23/13		
AM-5600 PCT	Synthesis of Olefins	Susan Schofer Adam Safir Roberto Vazquez	PCT/US2012/067027	11/29/12	WO 2013/082264	06/06/13		
AM-5900 PCT	Polymerization of Compositions Comprising a Farnesene	Joseph G. Doolan Adam Safir	PCT/US2012/069333	12/13/12	WO 2013/126129	08/29/13		

As of: September 27, 2013

*Indicates Total Collateral.

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
AM-6100 PCT	Drilling Fluids Comprising Farnesane and/or Farnesene	Jason Wells Joseph G. Doolan	PCT/US2012/068054	12/06/12	WO 2013/095934	06/27/13		
AM-6200 PCT	Oxygen Scavengers	Daniel Batzel Adam Safir Jeffrey D. Black Gianluca Ferrari Robert Morford Wenxia Zhu	PCT/US2012/047257	07/18/12	WO 2013/028289	02/28/13		
AM-6201 PCT	Oxygen Scavengers	Daniel Batzel Adam Safir Jeffrey D. Black Gianluca Ferrari Robert Morford Wenxia Zhu	PCT/US2012/047259	07/18/12	WO 2013/028290	02/28/13		
AM-6300 PCT	Methods for Stabilizing Heterologous Production of Non-Catabolic Compounds	Adam Meadows Hanxiao Jiang	PCT/US2013/054030	08/07/13				
AM-6310 PCT	Methods for Stabilizing Heterologous Production of Non-Catabolic Compounds	Adam Meadows Hanxiao Jiang	PCT/US2013/054028	08/07/13				
AM-6400 P1	Use of Phosphoketolase and Phophotransacetylase for Production of Acetyl-Coenzyme A Derived Compounds		61/800,356	03/15/13				

As of: September 27, 2013

*Indicates Total Collateral.

II. Patents and Patent Applications Licensed from Arkion

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
AR-100	Method of Producing Geranylgeraniol	James R. Millis Julie Maurina-Brunker Thomas W. McMullin	US 09/350,275	07/06/99			US 6,531,303	03/11/03
AR-100 C1A	Production of Farnesol and Geranylgeraniol	James R. Millis Julie Maurina-Brunker Thomas W. McMullin	US 09/909,558	07/20/01	US 2003/0092144	05/15/03	US 6,689,593	02/10/04
AR-100 C2	Production of Isoprenoids	James R. Millis Julie Maurina-Brunker Thomas W. McMullin	US 11/753,399	05/24/07	US 2007/0238160	10/11/07	US 8,241,888	08/14/12
AR-100 C2 D1	Production of Isoprenoids	James R. Millis Julie Maurina-Brunker Thomas W. McMullin	US 12/510,041	07/27/09	US 2010/0035329	02/11/10	US 8,236,552	08/07/12
AR-100 C3	Production of Isoprenoids	James R. Millis Julie Maurina-Brunker Thomas W. McMullin	US 11/753,254	05/24/07	US 2007/0238159	10/11/07	US 7,842,497	11/30/10
AR-100 C3 C1	Production of Isoprenoids	James R. Millis Julie Maurina-Brunker Thomas W. McMullin	US 12/942,723	11/09/10	US 2011/0059515	03/10/11	US 7,927,861	04/19/11
AR-100 C4	Production of Isoprenoids	James R. Millis Julie Maurina-Brunker Thomas W. McMullin	US 11/753,301	05/24/07	US 2007/0254354	11/01/07	US 7,838,279	11/23/10
AR-100 C4 C1	Production of Isoprenoids	James R. Millis Julie Maurina-Brunker Thomas W. McMullin	US 12/942,809	11/09/10	US 2011/0059516	03/10/11	US 7,927,862	04/19/11
AR-100 C4 C2	Production of Isoprenoids	James R. Millis Julie Maurina-Brunker Thomas W. McMullin	US 13/089,267	04/18/11	US 2011/0195470	08/11/11		
AR-100 C4 C3	Production of Isoprenoids	James R. Millis Julie Maurina-Brunker Thomas W. McMullin	US 13/865,072	04/17/13				
AR-100 C5	Production of Isoprenoids	James R. Millis Julie Maurina-Brunker Thomas W. McMullin	US 11/752,933	05/24/07	US 2007/0231861	10/04/07	US 7,718,417	05/18/10

As of: September 27, 2013

*Indicates Total Collateral.

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
AR-100 C6	Production of Isoprenoids	James R. Millis Julie Maurina-Brunker Thomas W. McMullin	US 11/752,931	05/24/07	US 2007/0238157	10/11/07	US 7,732,161	06/08/10
AR-100 CA	Method of Vitamin Production	James R. Millis Julie Maurina-Brunker Thomas W. McMullin	CA 2,331,343					
AR-100 EP1	Production of Farnesol and Geranylgeraniol	James R. Millis Julie Maurina-Brunker Thomas W. McMullin	EP 08003596.7				EP 1947189	12/01/10
AR-100 EP1-CH	Production of Farnesol and Geranylgeraniol	James R. Millis Julie Maurina-Brunker Thomas W. McMullin	EP 08003596.7				EP 1947189	12/01/10
AR-100 EP1-DE	Production of Farnesol and Geranylgeraniol	James R. Millis Julie Maurina-Brunker Thomas W. McMullin	EP 08003596.7				EP 1947189	12/01/10
AR-100 EP1-DK	Production of Farnesol and Geranylgeraniol	James R. Millis Julie Maurina-Brunker Thomas W. McMullin	EP 08003596.7				EP 1947189	12/01/10
AR-100 EP1-ES	Production of Farnesol and Geranylgeraniol	James R. Millis Julie Maurina-Brunker Thomas W. McMullin	EP 08003596.7				EP 1947189	12/01/10
AR-100 EP1-FR	Production of Farnesol and Geranylgeraniol	James R. Millis Julie Maurina-Brunker Thomas W. McMullin	EP 08003596.7				EP 1947189	12/01/10
AR-100 EP1-GB	Production of Farnesol and Geranylgeraniol	James R. Millis Julie Maurina-Brunker Thomas W. McMullin	EP 08003596.7				EP 1947189	12/01/10
AR-100 EP1-IE	Production of Farnesol and Geranylgeraniol	James R. Millis Julie Maurina-Brunker Thomas W. McMullin	EP 08003596.7				EP 1947189	12/01/10
AR-100 EP1-IT	Production of Farnesol and Geranylgeraniol	James R. Millis Julie Maurina-Brunker Thomas W. McMullin	EP 08003596.7				EP 1947189	12/01/10

As of: September 27, 2013

*Indicates Total Collateral.

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
AR-100 EP1-LU	Production of Farnesol and Geranylgeraniol	James R. Millis Julie Maurina-Brunker Thomas W. McMullin	EP 08003596.7				EP 1947189	12/01/10
AR-100 EP1-MC	Production of Farnesol and Geranylgeraniol	James R. Millis Julie Maurina-Brunker Thomas W. McMullin	EP 08003596.7				EP 1947189	12/01/10
AR-100 EP1-NL	Production of Farnesol and Geranylgeraniol	James R. Millis Julie Maurina-Brunker Thomas W. McMullin	EP 08003596.7				EP 1947189	12/01/10
AR-100 EP1-SE	Production of Farnesol and Geranylgeraniol	James R. Millis Julie Maurina-Brunker Thomas W. McMullin	EP 08003596.7				EP 1947189	12/01/10
AR-100 EP2	Production of Farnesol and Geranylgeraniol	James R. Millis Julie Maurina-Brunker Thomas W. McMullin	EP 09004155.9		EP 2100963	09/16/09	EP 2100963	12/14/11
AR-100 EP2-CH	Production of Farnesol and Geranylgeraniol	James R. Millis Julie Maurina-Brunker Thomas W. McMullin	EP 09004155.9		EP 2100963	09/16/09	EP 2100963	12/14/11
AR-100 EP2-DE	Production of Farnesol and Geranylgeraniol	James R. Millis Julie Maurina-Brunker Thomas W. McMullin	EP 09004155.9		EP 2100963	09/16/09	EP 2100963	12/14/11
AR-100 EP2-DK	Production of Farnesol and Geranylgeraniol	James R. Millis Julie Maurina-Brunker Thomas W. McMullin	EP 09004155.9		EP 2100963	09/16/09	EP 2100963	12/14/11
AR-100 EP2-ES	Production of Farnesol and Geranylgeraniol	James R. Millis Julie Maurina-Brunker Thomas W. McMullin	EP 09004155.9		EP 2100963	09/16/09	EP 2100963	12/14/11
AR-100 EP2-FR	Production of Farnesol and Geranylgeraniol	James R. Millis Julie Maurina-Brunker Thomas W. McMullin	EP 09004155.9		EP 2100963	09/16/09	EP 2100963	12/14/11
AR-100 EP2-GB	Production of Farnesol and Geranylgeraniol	James R. Millis Julie Maurina-Brunker Thomas W. McMullin	EP 09004155.9		EP 2100963	09/16/09	EP 2100963	12/14/11

As of: September 27, 2013

*Indicates Total Collateral.

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
AR-100 EP2-IE	Production of Farnesol and Geranylgeraniol	James R. Millis Julie Maurina-Brunker Thomas W. McMullin	EP 09004155.9		EP 2100963	09/16/09	EP 2100963	12/14/11
AR-100 EP2-IT	Production of Farnesol and Geranylgeraniol	James R. Millis Julie Maurina-Brunker Thomas W. McMullin	EP 09004155.9		EP 2100963	09/16/09	EP 2100963	12/14/11
AR-100 EP2-LU	Production of Farnesol and Geranylgeraniol	James R. Millis Julie Maurina-Brunker Thomas W. McMullin	EP 09004155.9		EP 2100963	09/16/09	EP 2100963	12/14/11
AR-100 EP2-MC	Production of Farnesol and Geranylgeraniol	James R. Millis Julie Maurina-Brunker Thomas W. McMullin	EP 09004155.9		EP 2100963	09/16/09	EP 2100963	12/14/11
AR-100 EP2-NL	Production of Farnesol and Geranylgeraniol	James R. Millis Julie Maurina-Brunker Thomas W. McMullin	EP 09004155.9		EP 2100963	09/16/09	EP 2100963	12/14/11
AR-100 EP2-SE	Production of Farnesol and Geranylgeraniol	James R. Millis Julie Maurina-Brunker Thomas W. McMullin	EP 09004155.9		EP 2100963	09/16/09	EP 2100963	12/14/11
AR-100 EP3	Production of Farnesol and Geranylgeraniol	James R. Millis Julie Maurina-Brunker Thomas W. McMullin	EP 10180179.3		EP 2305825	05/16/11		
AR-100 JP	Production of Farnesol and Geranylgeraniol	James R. Millis Julie Maurina-Brunker Thomas W. McMullin	JP 2000-558056				JP 4,579,415	09/03/10
AR-100 MX	Production of Farnesol and Geranylgeraniol	James R. Millis Julie Maurina-Brunker Thomas W. McMullin	MX PA/a/2001/000216				MX 219130	02/10/04
AR-100 MX C1	Production of Farnesol and Geranylgeraniol	James R. Millis Julie Maurina-Brunker Thomas W. McMullin	MX PA/a/2004/002408				MX 276941	06/28/10
AR-100 MX C1D1	Production of Farnesol and Geranylgeraniol	James R. Millis Julie Maurina-Brunker Thomas W. McMullin	MX/a/2008/011194					

As of: September 27, 2013

*Indicates Total Collateral.

III. Patents and Patent Applications Acquired from Draths

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
DR-100	Preparation of Trans, Trans Muconic Acid and Trans, Trans Muconates	John W. Frost Adeline Miermont Dirk Schweitzer Vu Bui	US 12/816,481	06/16/10	US 2010/0314243	12/16/10	US 8,426,639	04/23/13
DR-300 PCT	Methods for Making Cyclic Amide Monomer, Related Derivatives, and Methods	Douglas A. Wicks	PCT/US2009/051753	07/24/09	WO 2010/011967	01/28/10		
DR-300 BR	Methods for Making Cyclic Amide Monomer, Related Derivatives, and Methods	Douglas A. Wicks	BR PI0911733-4	01/24/11				
DR-300 CN	Methods for Making Cyclic Amide Monomer, Related Derivatives, and Methods	Douglas A. Wicks	CN 200980129042.2	01/24/11	CN 102105450A	06/22/11		
DR-300 EP	Methods for Making Cyclic Amide Monomer, Related Derivatives, and Methods	Douglas A. Wicks	EP 09790821.4	02/22/11	EP 2318373	05/11/11		
DR-300 IN	Methods for Making Cyclic Amide Monomer, Related Derivatives, and Methods	Douglas A. Wicks	IN 0372/KOLNP/2011	01/24/11	IN 372/KOLNP/11	04/01/11		
DR-300 JP	Methods for Making Cyclic Amide Monomer, Related Derivatives, and Methods	Douglas A. Wicks	JP 2011-520239	01/21/11	JP 2011-529087	12/01/11		
DR-300 KR	Methods for Making Cyclic Amide Monomer, Related Derivatives, and Methods	Douglas A. Wicks	KR 10-201-7004203	02/23/11				

As of: September 27, 2013

*Indicates Total Collateral.

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
DR-500 PCT	Methods for Producing Dodecanedioic Acid and Derivatives Thereof	John W. Frost James Millis Zhenyu Tang	PCT/US2010/021894	01/22/10	WO 2010/085712	07/29/10		
DR-500 BR	Methods for Producing Dodecanedioic Acid and Derivatives Thereof	John W. Frost James Millis Zhenyu Tang	BR PI 1005364-6	07/21/11				
DR-500 CN	Methods for Producing Dodecanedioic Acid and Derivatives Thereof	John W. Frost James Millis Zhenyu Tang	CN 201080009713.4	08/30/11				
DR-500 EP	Methods for Producing Dodecanedioic Acid and Derivatives Thereof	John W. Frost James Millis Zhenyu Tang	EP 10701303.9	08/09/11	EP 2389349	11/30/11		
DR-500 IN	Methods for Producing Dodecanedioic Acid and Derivatives Thereof	John W. Frost James Millis Zhenyu Tang	IN 3022/KOLNP/2011	07/18/11				
DR-500 JP	Methods for Producing Dodecanedioic Acid and Derivatives Thereof	John W. Frost James Millis Zhenyu Tang	JP 2011-548161	07/20/11	JP 2011-548161	07/12/12		
DR-500 KR	Methods for Producing Dodecanedioic Acid and Derivatives Thereof	John W. Frost James Millis Zhenyu Tang	KR 10-2011-7019342	08/19/11				
DR-600 PCT	Cyclohexene-1,4-Carboxylates	John W. Frost Adeline Miermont Dirk Schweitzer Vu Bui Douglas A. Wicks	PCT/US2010/038783	06/16/10	WO 2010/148063	12/23/10		
DR-600 AU	Cyclohexene-1,4-Carboxylates	John W. Frost Adeline Miermont Dirk Schweitzer Vu Bui Douglas A. Wicks	AU 2010260112	12/12/11				

As of: September 27, 2013

*Indicates Total Collateral.

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
DR-600 BR	Cyclohexene-1,4-Carboxylates	John W. Frost Adeline Miermont Dirk Schweitzer Vu Bui Douglas A. Wicks	BR P11009655-8	12/15/11				
DR-600 CA	Cyclohexene-1,4-Carboxylates	John W. Frost Adeline Miermont Dirk Schweitzer Vu Bui Douglas A. Wicks	CA 2,765,736	12/16/11				
DR-600 CN	Cyclohexene-1,4-Carboxylates	John W. Frost Adeline Miermont Dirk Schweitzer Vu Bui Douglas A. Wicks	CN 201080036355.6	02/15/12	CN 102725258A	10/10/12		
DR-600 EP	Cyclohexene-1,4-Carboxylates	John W. Frost Adeline Miermont Dirk Schweitzer Vu Bui Douglas A. Wicks	EP 10726757.7	12/29/11	EP 2443083	04/25/12		
DR-600 IN	Cyclohexene-1,4-Carboxylates	John W. Frost Adeline Miermont Dirk Schweitzer Vu Bui Douglas A. Wicks	IN 9525/CHENP/11	12/19/11	IN 9525/CHENP/11	03/29/13		
DR-600 JP	Cyclohexene-1,4-Carboxylates	John W. Frost Adeline Miermont Dirk Schweitzer Vu Bui Douglas A. Wicks	JP 2012-530144	12/14/11	JP 2012-516231	11/29/12		
DR-600 KR	Cyclohexene-1,4-Carboxylates	John W. Frost Adeline Miermont Dirk Schweitzer Vu Bui Douglas A. Wicks	KR 10-2012-7001041	01/13/12				

As of: September 27, 2013

*Indicates Total Collateral.

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
DR-600 MX	Cyclohexene-1,4-Carboxylates	John W. Frost Adeline Miermont Dirk Schweitzer Vu Bui Douglas A. Wicks	MX/a/11/014007	12/16/11				
DR-600 ZA	Cyclohexene-1,4-Carboxylates	John W. Frost Adeline Miermont Dirk Schweitzer Vu Bui Douglas A. Wicks	ZA 2012/00261	01/12/12			ZA 2012/00261	10/31/12
DR-700	Cyclohexane-1,4-Carboxylates	John W. Frost Adeline Miermont Dirk Schweitzer Vu Bui	US 12/816,742	06/16/10			US 8,367,859	02/05/13
DR-800	Novel Terephthalic and trimellitic Based Acids and Carboxylate Derivatives Thereof	John W. Frost Adeline Miermont Dirk Schweitzer Vu Bui	US 12/816,763	06/16/10	US 2011/0288311	11/24/11	US 8,367,858	02/05/13
DR-900	Biobased Polyesters	John W. Frost Adeline Miermont Dirk Schweitzer Vu Bu Douglas A. Wicks	US 12/816,701	06/16/10	US 2011/0288263	11/24/11	US 8,415,496	04/09/13
DR-1000	Sulfonation of Polyhydroxyaromatics	John W. Frost Vu Bui	US 12/859,922	08/20/10	US 2011/046412	02/24/11	US 8,492,581	07/23/13
DR-1100 PCT	Methods for Producing Isomers of Muconic Acid and Muconate Salts	Vu Bui Man Kit Lau Doug Macrae	PCT/US2011/020681	01/10/11	WO 2011/085311	07/14/11		
DR-1100 BR	Methods for Producing Isomers of Muconic Acid and Muconate Salts	Vu Bui Man Kit Lau Doug Macrae	BR 112012016855-0	07/12/12				
DR-1100 CA	Methods for Producing Isomers of Muconic Acid and Muconate Salts	Vu Bui Man Kit Lau Doug Macrae	CA 2,786,405	07/04/12				

As of: September 27, 2013

*Indicates Total Collateral.

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
DR-1100 CN	Methods for Producing Isomers of Muconic Acid and Muconate Salts	Vu Bui Man Kit Lau Doug Macrae	CN 201180012960.4	09/07/12	CN 102985537	03/20/13		
DR-1100 EP	Methods for Producing Isomers of Muconic Acid and Muconate Salts	Vu Bui Man Kit Lau Doug Macrae	EP 11700591.8	07/17/12	EP 2521770	11/14/12		
DR-1100 IN	Methods for Producing Isomers of Muconic Acid and Muconate Salts	Vu Bui Man Kit Lau Doug Macrae	IN 2007/KOLNP/2012	08/02/12				
DR-1100 JP	Methods for Producing Isomers of Muconic Acid and Muconate Salts	Vu Bui Man Kit Lau Doug Macrae	JP 2012-548206	07/05/12	JP 2013-516196	05/13/13		
DR-1100 MX	Methods for Producing Isomers of Muconic Acid and Muconate Salts	Vu Bui Man Kit Lau Doug Macrae	MX/a/2012/007944	07/06/12	MX/a/2012/007944	09/17/12		
DR-1100 US	Methods for Producing Isomers of Muconic Acid and Muconate Salts	Vu Bui Man Kit Lau Doug Macrae	US 13/518,534	06/22/12 371(C): 10/16/12	US 2013/0030215	01/31/13		
DR-1700 PCT	Process For Preparing Hexamethylenediamine and Polyamides Therefrom		PCT/US2012/032741	04/09/12	WO 2012/141993	10/18/12		
DR-1801	Process For Preparing Caprolactam and Polyamides Therefrom	Laetitia Coudray Vu P. Bui John W. Frost Dirk Schweitzer	US 13/442,306	04/09/12	US 2013/0085255	04/04/13		
DR-1801 PCT	Process For Preparing Caprolactam and Polyamides Therefrom	Laetitia Coudray Vu P. Bui John W. Frost Dirk Schweitzer	PCT/US2012/032774	04/09/12	WO 2012/141997	10/18/12		

As of: September 27, 2013

*Indicates Total Collateral.

IV. Patents and Patent Applications Licensed from the University of Maryland

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
MA-100 D1	Methods of Increasing or Decreasing Carotenoids and Other Isoprenoids Using IPP Isomerase	Francis X. Cunningham, Jr. Zairen Sun	US 08/937,155	09/25/97			US 6,524,811	02/25/03
MA-110	Methods of Increasing or Decreasing Carotenoids and Other Isoprenoids Using IPP Isomerase	Francis X. Cunningham, Jr. Zairen Sun	US 09/323,998	06/02/99			US 6,642,021	11/04/03

V. Patents and Patent Applications Licensed from the University of California

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
UC-100	Biosynthesis of Isopentenyl Pyrophosphate	Jay D. Keasling Vincent J. Martin Douglas J. Pitera Seon-Won Kim Sydnor T. Withers III Yasuo Yoshikuni Jack D. Newman Artem V. Khlebnikov	US 10/006,909	12/06/01	US 2003/0148479	08/07/03	US 7,172,886	02/06/07
UC-100 C1	Isolated Mevalonate Pathway Enzyme Nucleic Acids	Jay D. Keasling Vincent J. Martin Douglas J. Pitera Seon-Won Kim Sydnor T. Withers III Yasuo Yoshikuni Jack D. Newman Artem V. Khlebnikov	US 11/469,587	09/01/06	US 2007/0166782	07/19/07	US 7,667,017	02/23/10

As of: September 27, 2013

*Indicates Total Collateral.

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
UC-100 C2	Methods for Synthesizing Mevalonate	Jay D. Keasling Vincent J. Martin Douglas J. Pitera Seon-Won Kim Sydnor T. Withers III Yasuo Yoshikuni Jack D. Newman Artem V. Khlebnikov	US 11/610,690	12/14/06	US 2007/0092931	04/26/07	US 7,622,283	11/24/09
UC-100 D1	Biosynthesis of Isopentenyl Pyrophosphate	Jay D. Keasling Vincent J. Martin Douglas J. Pitera Seon-Won Kim Sydnor T. Withers III Yasuo Yoshikuni Jack D. Newman Artem V. Khlebnikov	US 11/610,337	12/13/06	US 2007/009921	05/03/07	US 7,622,282	11/24/09
UC-100 D2	Host Cells for Production of Isoprenoid Compounds	Jay D. Keasling Vincent J. Martin Douglas J. Pitera Seon-Won Kim Sydnor T. Withers III Yasuo Yoshikuni Jack D. Newman Artem V. Khlebnikov	US 11/610,686	12/14/06	US 2007/0077616	04/05/07	US 7,736,882	06/15/10
UC-100 D2C1	Host Cells for Production of Isoprenoid Compounds	Jay D. Keasling Vincent J. Martin Douglas J. Pitera Seon-Won Kim Sydnor T. Withers III Yasuo Yoshikuni Jack D. Newman Artem V. Khlebnikov	US 12/576,068	10/08/09	US 2010/0112671	05/06/10	US 7,915,026	03/29/11

As of: September 27, 2013

*Indicates Total Collateral.

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
UC-100 D2C2	Host Cells for Production of Isoprenoid Compounds	Jay D. Keasling Vincent J. Martin Douglas J. Pitera Seon-Won Kim Sydnor T. Withers III Yasuo Yoshikuni Jack D. Newman Artem V. Khlebnikov	US 13/027,517	02/15/11	US 2011/0229958	09/22/11	US 8,288,147	10/16/12
UC-110	Biosynthesis of Amorpha-4,11-diene	Jay D. Keasling Vincent J. Martin Douglas J. Pitera Sydnor T. Withers III Jack D. Newman	US 10/411,066	04/09/04	US 2004/0005678	01/08/04	US 7,192,751	03/20/07
UC-400	Method for Enhancing Production of Isoprenoid Compounds	Jay D. Keasling Jack D. Newman Douglas J. Pitera	US 11/134,705	05/20/05	US 2006/0079476	04/13/06	US 7,183,089	02/27/07
UC-400 C1	Method for Enhancing Production of Isoprenoid Compounds	Jay D. Keasling Jack D. Newman Douglas J. Pitera	US 11/624,094	01/17/07	US 2009/0004724	01/01/09	US 7,670,825	03/02/10
UC-400 PCT	Method for Enhancing Production of Isoprenoid Compounds	Jay D. Keasling Jack D. Newman Douglas J. Pitera	PCT/US2005/017874	05/20/05	WO 2006/085899	08/17/06		
UC-400 AU	Method for Enhancing Production of Isoprenoid Compounds	Jay D. Keasling Jack D. Newman Douglas J. Pitera	AU 2005327292				AU 2005327292	02/17/11
UC-400 BR	Method for Enhancing Production of Isoprenoid Compounds	Jay D. Keasling Jack D. Newman Douglas J. Pitera	BR PI0510115-8		BR PI051011-8	09/25/07		
UC-400 CA	Method for Enhancing Production of Isoprenoid Compounds	Jay D. Keasling Jack D. Newman Douglas J. Pitera	CA 2,567,547				CA 2,567,547	10/23/12
UC-400 CN	Method for Enhancing Production of Isoprenoid Compounds	Jay D. Keasling Jack D. Newman Douglas J. Pitera	CN 200580024343.0		CN 101023181	08/22/07		

As of: September 27, 2013

*Indicates Total Collateral.

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
UC-400 EP	Method for Enhancing Production of Isoprenoid Compounds	Jay D. Keasling Jack D. Newman Douglas J. Pitera	EP 05857432.8		EP 1765418	03/28/07	EP 1765418	12/14/11
UC-400 EP D1	Method for Enhancing Production of Isoprenoid Compounds	Jay D. Keasling Jack D. Newman Douglas J. Pitera	EP 10177421.4		EP 2365090	09/14/11		
UC-400 EP-DE	Method for Enhancing Production of Isoprenoid Compounds	Jay D. Keasling Jack D. Newman Douglas J. Pitera	EP 05857432.8		EP 1765418	03/28/07	EP 1765418	12/14/11
UC-400 EP-ES	Method for Enhancing Production of Isoprenoid Compounds	Jay D. Keasling Jack D. Newman Douglas J. Pitera	EP 05857432.8		EP 1765418	03/28/07	EP 1765418	12/14/11
UC-400 EP-FR	Method for Enhancing Production of Isoprenoid Compounds	Jay D. Keasling Jack D. Newman Douglas J. Pitera	EP 05857432.8		EP 1765418	03/28/07	EP 1765418	12/14/11
UC-400 EP-GB	Method for Enhancing Production of Isoprenoid Compounds	Jay D. Keasling Jack D. Newman Douglas J. Pitera	EP 05857432.8		EP 1765418	03/28/07	EP 1765418	12/14/11
UC-400 EP-IE	Method for Enhancing Production of Isoprenoid Compounds	Jay D. Keasling Jack D. Newman Douglas J. Pitera	EP 05857432.8		EP 1765418	03/28/07	EP 1765418	12/14/11
UC-400 EP-IT	Method for Enhancing Production of Isoprenoid Compounds	Jay D. Keasling Jack D. Newman Douglas J. Pitera	EP 05857432.8		EP 1765418	03/28/07	EP 1765418	12/14/11
UC-400 JP	Method for Enhancing Production of Isoprenoid Compounds	Jay D. Keasling Jack D. Newman Douglas J. Pitera	JP 2007-527501		JP 2008-500063	01/10/08	JP 4,926,061	05/09/12
UC-400 MX	Method for Enhancing Production of Isoprenoid Compounds	Jay D. Keasling Jack D. Newman Douglas J. Pitera	MX PA/a/2006/013502				MX 279706	10/05/10
UC-400 VN	Method for Enhancing Production of Isoprenoid Compounds	Jay D. Keasling Jack D. Newman Douglas J. Pitera	VN 1-2006-02031		VN 14171	02/26/07		

As of: September 27, 2013

*Indicates Total Collateral.

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
UC-400 ZA	Method for Enhancing Production of Isoprenoid Compounds	Jay D. Keasling Jack D. Newman Douglas J. Pitera	ZA 2006/10171				ZA 2006/10171	04/30/08
UC-500 PCT	Genetically Modified Host Cells and Use of Same for Producing Isoprenoid Compounds	Jay D. Keasling James Kirby Eric M. Paradise	PCT/US2005/026190	07/21/05	WO 2006/014837	02/09/06		
UC-500 AU	Genetically Modified Host Cells and Use of Same for Producing Isoprenoid Compounds	Jay D. Keasling James Kirby Eric M. Paradise	AU 2005269556				AU 2005269556	02/09/12
UC-500 BR	Genetically Modified Host Cells and Use of Same for Producing Isoprenoid Compounds	Jay D. Keasling James Kirby Eric M. Paradise	BR PI0513837-0		BR Journal No. 1950	05/20/08		
UC-500 CA	Genetically Modified Host Cells and Use of Same for Producing Isoprenoid Compounds	Jay D. Keasling James Kirby Eric M. Paradise	CA 2,574,593					
UC-500 EP	Genetically Modified Host Cells and Use of Same for Producing Isoprenoid Compounds	Jay D. Keasling James Kirby Eric M. Paradise	EP 05775484.8		EP 1778831	05/02/07	EP 1778831	05/23/12
UC-500 EP-DE	Genetically Modified Host Cells and Use of Same for Producing Isoprenoid Compounds	Jay D. Keasling James Kirby Eric M. Paradise	EP 05775484.8		EP 1778831	05/02/07	EP 1778831	05/23/12
UC-500 EP-ES	Genetically Modified Host Cells and Use of Same for Producing Isoprenoid Compounds	Jay D. Keasling James Kirby Eric M. Paradise	EP 05775484.8		EP 1778831	05/02/07	EP 1778831	05/23/12
UC-500 EP-FR	Genetically Modified Host Cells and Use of Same for Producing Isoprenoid Compounds	Jay D. Keasling James Kirby Eric M. Paradise	EP 05775484.8		EP 1778831	05/02/07	EP 1778831	05/23/12

As of: September 27, 2013

*Indicates Total Collateral.

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
UC-500 EP-GB	Genetically Modified Host Cells and Use of Same for Producing Isoprenoid Compounds	Jay D. Keasling James Kirby Eric M. Paradise	EP 05775484.8		EP 1778831	05/02/07	EP 1778831	05/23/12
UC-500 EP-IT	Genetically Modified Host Cells and Use of Same for Producing Isoprenoid Compounds	Jay D. Keasling James Kirby Eric M. Paradise	EP 05775484.8		EP 1778831	05/02/07	EP 1778831	05/23/12
UC-500 JP	Genetically Modified Host Cells and Use of Same for Producing Isoprenoid Compounds	Jay D. Keasling James Kirby Eric M. Paradise	JP 2007-523676		JP 2008-507974	03/21/08		
UC-500 MX	Genetically Modified Host Cells and Use of Same for Producing Isoprenoid Compounds	Jay D. Keasling James Kirby Eric M. Paradise	MX/a/2007/000973					
UC-500 US	Genetically Modified Host Cells and Use of Same for Producing Isoprenoid Compounds	Jay D. Keasling James Kirby Eric M. Paradise	US 11/571,315	11/13/07	US 2008/0171378	07/17/08		
UC-500 VN	Genetically Modified Host Cells and Use of Same for Producing Isoprenoid Compounds	Jay D. Keasling James Kirby Eric M. Paradise	VN 1-2007-00356		VN 14793	06/25/07		
UC-500 ZA	Genetically Modified Host Cells and Use of Same for Producing Isoprenoid Compounds	Jay D. Keasling James Kirby Eric M. Paradise	ZA 2007/00753		ZA 2007/00753	05/28/08		
UC-600	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	Dae-Kyun Ro Karyn Newman Eric M. Paradise Jay D. Keasling Mario Ouellet Rachel Eachus K. Ho T. Ham	US 11/917,875	06/29/06	US 2010/0218283	08/26/10	US 8,163,980	04/24/12

As of: September 27, 2013

*Indicates Total Collateral.

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
UC-600 D1	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	Dae-Kyun Ro Karyn Newman Eric M. Paradise Jay D. Keasling Mario Ouellet Rachel Eachus K. Ho T. Ham	US 13/426,387	03/21/12	US 2012/0288905	11/15/12		
UC-600 PCT	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	Dae-Kyun Ro Karyn Newman Eric M. Paradise Jay D. Keasling Mario Ouellet Rachel Eachus K. Ho T. Ham	PCT/US2006/025572	06/29/06	WO 2007/005604	01/11/07		
UC-600 AP	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	Dae-Kyun Ro Karyn Newman Eric M. Paradise Jay D. Keasling Mario Ouellet Rachel Eachus K. Ho T. Ham	AP/P/2008/004323	06/29/06				
UC-600 AP D1	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	Dae-Kyun Ro Karyn Newman Eric M. Paradise Jay D. Keasling Mario Ouellet Rachel Eachus K. Ho T. Ham	AP/P/2013/006962	07/09/13				

As of: September 27, 2013

*Indicates Total Collateral.

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
UC-600 BR	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	Dae-Kyun Ro Karyn Newman Eric M. Paradise Jay D. Keasling Mario Ouellet Rachel Eachus K. Ho T. Ham	BR PI0612411-9	06/29/06				
UC-600 CA	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	Dae-Kyun Ro Karyn Newman Eric M. Paradise Jay D. Keasling Mario Ouellet Rachel Eachus K. Ho T. Ham	CA 2,613,469	06/29/06				
UC-600 CN	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	Dae-Kyun Ro Karyn Newman Eric M. Paradise Jay D. Keasling Mario Ouellet Rachel Eachus K. Ho T. Ham	CN 200680024666.4	06/29/06	CN 101495499A	07/29/09		
UC-600 CN D1	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	Dae-Kyun Ro Karyn Newman Eric M. Paradise Jay D. Keasling Mario Ouellet Rachel Eachus K. Ho T. Ham	CN 201310335874.8	08/02/13				

As of: September 27, 2013

*Indicates Total Collateral.

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
UC-600 EG	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	Dae-Kyun Ro Karyn Newman Eric M. Paradise Jay D. Keasling Mario Ouellet Rachel Eachus K. Ho T. Ham	EG PCT/NA2008/000010	06/29/06				
UC-600 EP	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	Dae-Kyun Ro Karyn Newman Eric M. Paradise Jay D. Keasling Mario Ouellet Rachel Eachus K. Ho T. Ham	EP 06785959.5	06/29/06	EP 1919514	05/14/08	EP 1919514	05/16/12
UC-600 EP D1	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	Dae-Kyun Ro Karyn Newman Eric M. Paradise Jay D. Keasling Mario Ouellet Rachel Eachus K. Ho T. Ham	EP 12158465.0	03/07/12	EP 2489672	08/22/12		
UC-600 EP-AT	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	Dae-Kyun Ro Karyn Newman Eric M. Paradise Jay D. Keasling Mario Ouellet Rachel Eachus K. Ho T. Ham	EP 06785959.5	06/29/06	EP 1919514	05/14/08	EP 1919514	05/16/12

As of: September 27, 2013

*Indicates Total Collateral.

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
UC-600 EP-BE	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	Dae-Kyun Ro Karyn Newman Eric M. Paradise Jay D. Keasling Mario Ouellet Rachel Eachus K. Ho T. Ham	EP 06785959.5	06/29/06	EP 1919514	05/14/08	EP 1919514	05/16/12
UC-600 EP-BG	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	Dae-Kyun Ro Karyn Newman Eric M. Paradise Jay D. Keasling Mario Ouellet Rachel Eachus K. Ho T. Ham	EP 06785959.5	06/29/06	EP 1919514	05/14/08	EP 1919514	05/16/12
UC-600 EP-CH	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	Dae-Kyun Ro Karyn Newman Eric M. Paradise Jay D. Keasling Mario Ouellet Rachel Eachus K. Ho T. Ham	EP 06785959.5	06/29/06	EP 1919514	05/14/08	EP 1919514	05/16/12
UC-600 EP-CY	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	Dae-Kyun Ro Karyn Newman Eric M. Paradise Jay D. Keasling Mario Ouellet Rachel Eachus K. Ho T. Ham	EP 06785959.5	06/29/06	EP 1919514	05/14/08	EP 1919514	05/16/12

As of: September 27, 2013

*Indicates Total Collateral.

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
UC-600 EP-CZ	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	Dae-Kyun Ro Karyn Newman Eric M. Paradise Jay D. Keasling Mario Ouellet Rachel Eachus K. Ho T. Ham	EP 06785959.5	06/29/06	EP 1919514	05/14/08	EP 1919514	05/16/12
UC-600 EP-DE	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	Dae-Kyun Ro Karyn Newman Eric M. Paradise Jay D. Keasling Mario Ouellet Rachel Eachus K. Ho T. Ham	EP 06785959.5	06/29/06	EP 1919514	05/14/08	EP 1919514	05/16/12
UC-600 EP-DK	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	Dae-Kyun Ro Karyn Newman Eric M. Paradise Jay D. Keasling Mario Ouellet Rachel Eachus K. Ho T. Ham	EP 06785959.5	06/29/06	EP 1919514	05/14/08	EP 1919514	05/16/12
UC-600 EP-EE	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	Dae-Kyun Ro Karyn Newman Eric M. Paradise Jay D. Keasling Mario Ouellet Rachel Eachus K. Ho T. Ham	EP 06785959.5	06/29/06	EP 1919514	05/14/08	EP 1919514	05/16/12

As of: September 27, 2013

*Indicates Total Collateral.

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
UC-600 EP-ES	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	Dae-Kyun Ro Karyn Newman Eric M. Paradise Jay D. Keasling Mario Ouellet Rachel Eachus K. Ho T. Ham	EP 06785959.5	06/29/06	EP 1919514	05/14/08	EP 1919514	05/16/12
UC-600 EP-FI	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	Dae-Kyun Ro Karyn Newman Eric M. Paradise Jay D. Keasling Mario Ouellet Rachel Eachus K. Ho T. Ham	EP 06785959.5	06/29/06	EP 1919514	05/14/08	EP 1919514	05/16/12
UC-600 EP-FR	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	Dae-Kyun Ro Karyn Newman Eric M. Paradise Jay D. Keasling Mario Ouellet Rachel Eachus K. Ho T. Ham	EP 06785959.5	06/29/06	EP 1919514	05/14/08	EP 1919514	05/16/12
UC-600 EP-GB	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	Dae-Kyun Ro Karyn Newman Eric M. Paradise Jay D. Keasling Mario Ouellet Rachel Eachus K. Ho T. Ham	EP 06785959.5	06/29/06	EP 1919514	05/14/08	EP 1919514	05/16/12

As of: September 27, 2013

*Indicates Total Collateral.

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
UC-600 EP-GR	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	Dae-Kyun Ro Karyn Newman Eric M. Paradise Jay D. Keasling Mario Ouellet Rachel Eachus K. Ho T. Ham	EP 06785959.5	06/29/06	EP 1919514	05/14/08	EP 1919514	05/16/12
UC-600 EP-HU	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	Dae-Kyun Ro Karyn Newman Eric M. Paradise Jay D. Keasling Mario Ouellet Rachel Eachus K. Ho T. Ham	EP 06785959.5	06/29/06	EP 1919514	05/14/08	EP 1919514	05/16/12
UC-600 EP-IE	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	Dae-Kyun Ro Karyn Newman Eric M. Paradise Jay D. Keasling Mario Ouellet Rachel Eachus K. Ho T. Ham	EP 06785959.5	06/29/06	EP 1919514	05/14/08	EP 1919514	05/16/12
UC-600 EP-IS	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	Dae-Kyun Ro Karyn Newman Eric M. Paradise Jay D. Keasling Mario Ouellet Rachel Eachus K. Ho T. Ham	EP 06785959.5	06/29/06	EP 1919514	05/14/08	EP 1919514	05/16/12

As of: September 27, 2013

*Indicates Total Collateral.

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
UC-600 EP-IT	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	Dae-Kyun Ro Karyn Newman Eric M. Paradise Jay D. Keasling Mario Ouellet Rachel Eachus K. Ho T. Ham	EP 06785959.5	06/29/06	EP 1919514	05/14/08	EP 1919514	05/16/12
UC-600 EP-LT	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	Dae-Kyun Ro Karyn Newman Eric M. Paradise Jay D. Keasling Mario Ouellet Rachel Eachus K. Ho T. Ham	EP 06785959.5	06/29/06	EP 1919514	05/14/08	EP 1919514	05/16/12
UC-600 EP-LU	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	Dae-Kyun Ro Karyn Newman Eric M. Paradise Jay D. Keasling Mario Ouellet Rachel Eachus K. Ho T. Ham	EP 06785959.5	06/29/06	EP 1919514	05/14/08	EP 1919514	05/16/12
UC-600 EP-LV	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	Dae-Kyun Ro Karyn Newman Eric M. Paradise Jay D. Keasling Mario Ouellet Rachel Eachus K. Ho T. Ham	EP 06785959.5	06/29/06	EP 1919514	05/14/08	EP 1919514	05/16/12

As of: September 27, 2013

*Indicates Total Collateral.

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
UC-600 EP-MC	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	Dae-Kyun Ro Karyn Newman Eric M. Paradise Jay D. Keasling Mario Ouellet Rachel Eachus K. Ho T. Ham	EP 06785959.5	06/29/06	EP 1919514	05/14/08	EP 1919514	05/16/12
UC-600 EP-NL	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	Dae-Kyun Ro Karyn Newman Eric M. Paradise Jay D. Keasling Mario Ouellet Rachel Eachus K. Ho T. Ham	EP 06785959.5	06/29/06	EP 1919514	05/14/08	EP 1919514	05/16/12
UC-600 EP-PL	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	Dae-Kyun Ro Karyn Newman Eric M. Paradise Jay D. Keasling Mario Ouellet Rachel Eachus K. Ho T. Ham	EP 06785959.5	06/29/06	EP 1919514	05/14/08	EP 1919514	05/16/12
UC-600 EP-PT	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	Dae-Kyun Ro Karyn Newman Eric M. Paradise Jay D. Keasling Mario Ouellet Rachel Eachus K. Ho T. Ham	EP 06785959.5	06/29/06	EP 1919514	05/14/08	EP 1919514	05/16/12

As of: September 27, 2013

*Indicates Total Collateral.

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
UC-600 EP-RO	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	Dae-Kyun Ro Karyn Newman Eric M. Paradise Jay D. Keasling Mario Ouellet Rachel Eachus K. Ho T. Ham	EP 06785959.5	06/29/06	EP 1919514	05/14/08	EP 1919514	05/16/12
UC-600 EP-SE	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	Dae-Kyun Ro Karyn Newman Eric M. Paradise Jay D. Keasling Mario Ouellet Rachel Eachus K. Ho T. Ham	EP 06785959.5	06/29/06	EP 1919514	05/14/08	EP 1919514	05/16/12
UC-600 EP-SI	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	Dae-Kyun Ro Karyn Newman Eric M. Paradise Jay D. Keasling Mario Ouellet Rachel Eachus K. Ho T. Ham	EP 06785959.5	06/29/06	EP 1919514	05/14/08	EP 1919514	05/16/12
UC-600 EP-SK	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	Dae-Kyun Ro Karyn Newman Eric M. Paradise Jay D. Keasling Mario Ouellet Rachel Eachus K. Ho T. Ham	EP 06785959.5	06/29/06	EP 1919514	05/14/08	EP 1919514	05/16/12

As of: September 27, 2013

*Indicates Total Collateral.

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
UC-600 EP-TR	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	Dae-Kyun Ro Karyn Newman Eric M. Paradise Jay D. Keasling Mario Ouellet Rachel Eachus K. Ho T. Ham	EP 06785959.5	06/29/06	EP 1919514	05/14/08	EP 1919514	05/16/12
UC-600 ID	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	Dae-Kyun Ro Karyn Newman Eric M. Paradise Jay D. Keasling Mario Ouellet Rachel Eachus K. Ho T. Ham	ID W00200800058	06/29/06				
UC-600 IL	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	Dae-Kyun Ro Karyn Newman Eric M. Paradise Jay D. Keasling Mario Ouellet Rachel Eachus K. Ho T. Ham	IL 188376	06/29/06			IL 188376	04/01/13
UC-600 IN	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	Dae-Kyun Ro Karyn Newman Eric M. Paradise Jay D. Keasling Mario Ouellet Rachel Eachus K. Ho T. Ham	IN 0527/DELNP/2008	06/29/06				

As of: September 27, 2013

*Indicates Total Collateral.

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
UC-600 JP	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	Dae-Kyun Ro Karyn Newman Eric M. Paradise Jay D. Keasling Mario Ouellet Rachel Eachus K. Ho T. Ham	JP 2008-519611	06/29/06	JP 2009-504138	02/05/09		
UC-600 KR	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	Dae-Kyun Ro Karyn Newman Eric M. Paradise Jay D. Keasling Mario Ouellet Rachel Eachus K. Ho T. Ham	KR 10-2008-7002992	06/29/06				
UC-600 KR D1	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	Dae-Kyun Ro Karyn Newman Eric M. Paradise Jay D. Keasling Mario Ouellet Rachel Eachus K. Ho T. Ham	KR 10-2013-7011897	05/08/13				
UC-600 MG	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	Dae-Kyun Ro Karyn Newman Eric M. Paradise Jay D. Keasling Mario Ouellet Rachel Eachus K. Ho T. Ham	MG 2008/002	06/29/06				

As of: September 27, 2013

*Indicates Total Collateral.

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
UC-600 MX	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	Dae-Kyun Ro Karyn Newman Eric M. Paradise Jay D. Keasling Mario Ouellet Rachel Eachus K. Ho T. Ham	MX/a/2008/000200	06/29/06				
UC-600 MX D1	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	Dae-Kyun Ro Karyn Newman Eric M. Paradise Jay D. Keasling Mario Ouellet Rachel Eachus K. Ho T. Ham	MX/a/2012/007818	07/03/12				
UC-600 SG	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	Dae-Kyun Ro Karyn Newman Eric M. Paradise Jay D. Keasling Mario Ouellet Rachel Eachus K. Ho T. Ham	SG 200800019-2	06/29/06				
UC-600 SG D1	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	Dae-Kyun Ro Karyn Newman Eric M. Paradise Jay D. Keasling Mario Ouellet Rachel Eachus K. Ho T. Ham	SG 201108140-3	11/04/11	SG 176459	12/29/11		

As of: September 27, 2013

*Indicates Total Collateral.

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
UC-600 VN	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	Dae-Kyun Ro Karyn Newman Eric M. Paradise Jay D. Keasling Mario Ouellet Rachel Eachus K. Ho T. Ham	VN 1-2008-00230	06/29/06				
UC-600 ZA	Polynucleotides Encoding Isoprenoid-Modifying Enzymes and Methods of Use Thereof	Dae-Kyun Ro Karyn Newman Eric M. Paradise Jay D. Keasling Mario Ouellet Rachel Eachus K. Ho T. Ham	ZA 2008/00889	06/29/06			ZA 2008/00889	04/07/10
UC-1100 PCT	Production of Isoprenoids and Precursors Thereof	Jay D. Keasling Farnaz Nowroozi Douglas Pitera Jack Newman Jennifer Anthony Larry Anthony	PCT/US2007/020790	09/25/07	WO 2008/039499	04/03/08		
UC-1100 BR	Production of Isoprenoids and Precursors Thereof	Jay D. Keasling Farnaz Nowroozi Douglas Pitera Jack Newman Jennifer Anthony Larry Anthony	BR PI0716954-0					
UC-1100 EP	Production of Isoprenoids and Precursors Thereof	Jay D. Keasling Farnaz Nowroozi Douglas Pitera Jack Newman Jennifer Anthony Larry Anthony	EP 07838895.6		EP 2066778	06/10/09		

As of: September 27, 2013




*Indicates Total Collateral.

Amyris Ref No.	Title	Inventors	Application No.	Filing Date	Pub Number	Pub. Date	Patent Number	Issue Date
UC-1100 IN	Production of Isoprenoids and Precursors Thereof	Jay D. Keasling Farnaz Nowroozi Douglas Pitera Jack Newman Jennifer Anthony Larry Anthony	IN 2242/DELNP/2009					
UC-1100 US	Production of Isoprenoids and Precursors Thereof	Jay D. Keasling Farnaz Nowroozi Douglas Pitera Jack Newman Jennifer Anthony Larry Anthony	US 12/439,812		US 2010/0112672	05/06/10	US 8,257,957	09/04/12

As of: September 27, 2013


*Indicates Total Collateral.

VI. Trademarks

Mark	Class	Country	Application No.	Filing Date	Registration No.	Reg. Date	Exp. Date	Status
	4	US	77/008,832	09/27/06	3,418,982	04/29/08	04/29/18	Registered
	42	US	77/008,883	09/27/06	3,591,716	03/17/09	03/17/19	Registered
AMYRIS	3	US	77/648,755	01/13/09	4,031,996	09/27/11	09/27/21	Registered
AMYRIS	3	Internat'l	IR1136706	10/18/12	IR1136706	10/18/12		Registered
AMYRIS	3	BR	905268423	09/11/12				Pending
AMYRIS	3	EC	IR1136706	10/18/12				Pending
AMYRIS	3	JP	IR1136706	10/18/12				Pending
AMYRIS	4	US	77/008,889	09/27/06	3,418,984	04/29/08	04/29/18	Registered
AMYRIS	4	Internat'l	IR948423	12/20/07	IR948423	12/20/07		Registered
AMYRIS	4	AU	IR948423	12/20/07	IR948423	12/20/07		Registered
AMYRIS	4	BR	900766638	02/28/08				Allowed
AMYRIS	4	CN	IR948423	12/20/07	IR948423	12/20/07		Registered
AMYRIS	4	EC	IR948423	12/20/07	IR948423	12/20/07		Registered
AMYRIS	4	IN	1641699	01/16/08	1641699	03/31/09		Registered
AMYRIS	4	JP	IR948423	12/20/07	IR948423	12/20/07		Registered
AMYRIS	42	US	77/011,120	09/29/06	3,516,929	10/14/08		Registered
AMYRIS	42	Internat'l	IR948424	12/20/07	IR948424	12/20/07		Registered
AMYRIS	42	AU	IR948424	12/20/07	IR948424	12/20/07		Registered
AMYRIS	42	BR	900766654	02/28/08	900766654	08/09/01		Registered
AMYRIS	42	CN	IR948424	12/20/07	IR948424	12/20/07		Registered
AMYRIS	42	EC	IR948424	12/20/07	IR948424	12/20/07		Registered
AMYRIS	42	IN	1641698	01/16/08	164198	03/31/09		Registered
AMYRIS	42	JP	IR948424	12/20/07	IR948424	12/20/07		Registered
GREEN LANE	39	US	77/976,721	12/05/06	3,604,243	04/07/09		Registered
DIAL-A-BLEND	4	Brazil	900766719	02/28/08	900766719	08/09/11		Registered
DIAL-A-BLEND	4, 9	EC	6677967	02/04/08	006677967	01/08/09		Registered
	4	US	77/505,637	06/23/08	3,793,831	05/25/10		Registered

As of: September 27, 2013

*Indicates Total Collateral.

	42	US	77/505,634	06/23/08	3,793,830	05/25/10		Registered
NO COMPROMISE	1	US	77/749,465	06/01/09	3,846,212	09/07/10		Registered
NO COMPROMISE	1	BR	902155202	11/30/09				Allowed
NO COMPROMISE	1	EC	8703878	11/23/09	8703878	06/02/10		Registered
NO COMPROMISE	4	US	77/568,309	09/11/08	3,664,922	08/04/09		Registered
NO COMPROMISE	4	BR	901470945	02/20/09				Pending
NO COMPROMISE	4,39,40	EC	8135014	03/04/09	8135014	11/20/09		Registered
Citrus "Smell"	4	US	76/693,238	10/01/08	3,726,789	12/15/09		Registered
BIOFENE	1	US	77/818,383	09/02/09	3,894,976	12/21/10		Registered
DIESEL DE CANA	4	BR	902783580	07/19/10				Published
NEOSSANCE	1,3	US	85/541,582	02/13/12	4,209,630	09/18/12		Registered
NEOSSANCE	1,3	Internat'l	IR1133812	07/11/12	IR1133812	07/11/12		Registered
NEOSSANCE	1	Brazil	905060539	07/23/12				Pending
NEOSSANCE	3	Brazil	905060555	07/23/12				Pending
NEOSSANCE	1,3	EC	IR1133812	07/11/12				Pending
NEOSSANCE	1,3	JP	IR1133812	07/11/12	IR1133812	07/11/12		Registered
EVOSHIELD	4	US	85/536,417	02/07/12	4,302,622	03/12/13		Registered
CLEARLY PATCHOULI	3	US	85/631,181	05/21/12				Allowed
CLEARLY PATCHOULI	3	Internat'l	IR1143277	11/19/12	IR1143277	11/19/12		Registered
CLEARLY PATCHOULI	3	Brazil	905564602	11/21/12				Pending
CLEARLY PATCHOULI	3	EC	IR1143277	11/19/12				Pending

As of: September 27, 2013

*Indicates Total Collateral.

**SECTION 3(a) - PERSONS WHO HAVE RECEIVED GRANTED LICENSES THAT
COULD BE CONSIDERED MATERIAL AND WERE DISCLOSED IN THE COMPANY'S
PERIODIC FILINGS WITH THE SECURITIES AND EXCHANGE COMMISSION**

Amyris Brasil, Ltda.
Antibioticos, S.A.
Biomim do Brasil Nutricao Animal Ltda.
Centerchem, Inc.
Firmenich SA
Givaudan Schweiz AG
Glycotech, Inc.
International Flavors and Fragrances, Inc.
Kuraray Co., Ltd.
Laserson S.A.
M&G Finanziaria S.R.L.
Manufacture Francaise des Pneumatiques Michelin
Method Products, Inc.
National Renewable Energy Laboratory
Nikko Chemicals Co. Ltd.
Novvi LLC
One World Health
Petrobras Distribuidora S.A.
SMA Industria Quimica S.A. (with Usina Sao Martinho S.A.)
Soliance
Tate & Lyle Ingredients Americas, Inc.
The Defense Advanced Research Projects Agency
The Proctor and Gamble Company
Total Gas & Power USA, SAS
U.S. Department of Energy
Wilmar Trading Pte. Ltd.

EXHIBIT A:
FORM OF TERMINATION

**Total Energies Nouvelles Activités USA
4 Cours Michelet
92800 Puteaux France**

**Maxwell (Mauritius) Pte Ltd
60B Orchard Road #06-18
Tower 2, The Atrium @Orchard
Singapore 238891**

Amyris, Inc.
5885 Hollis Street, Suite 100
Emeryville, CA 94608
Attn: General Counsel

Ladies and Gentlemen:

Reference is made to the Amended and Restated Intellectual Property Security Agreement, dated as of October 2, 2013 (as amended, restated, modified or otherwise supplemented from time to time, the “**Security Agreement**”) among Amyris, Inc., Total Energies Nouvelles Activités USA (f/k/a/ Total Power & Gas USA, SAS), and Maxwell (Mauritius) Pte Ltd. Capitalized terms used herein and not defined herein, shall have the meanings assigned to such terms in the Security Agreement.

You are hereby notified that, pursuant to Section 9(c) of the Security Agreement, the Security Agreement is hereby terminated, you have no further obligations to the undersigned thereunder and the security interest granted therein, and each Secured Party’s rights and Company’s obligations under the 2012 Letter Agreement and the 2013 Letter Agreement with regard to any security interest created thereunder, are hereby automatically terminated and all rights to the Collateral shall immediately revert to Company. This notice terminates any obligations you may have to the undersigned with respect to the Security Agreement; however, nothing contained in this notice shall alter any obligations which you may otherwise owe to any Secured Party pursuant to any other agreement.

Very truly yours,

Total Energies Nouvelles Activités USA,
as Secured Party

By: _____
Name: _____
Title: _____

Maxwell (Mauritius) Pte Ltd,
as Secured Party

By: _____

Name: _____

Title: _____